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ABSTRACT 
 Cardiac dysfunction is one of the largest obstacles to effective cancer treatment. Not 
only do a growing number of cancer patients have significant cardiovascular risk factors at 
the time of diagnosis, but a number of targeted therapies can themselves cause cardiac 
dysfunction. These newer treatment options are also increasingly effective, placing a 
growing emphasis on post-cancer quality of life. In some instances, a patient may outlive his 
or her cancer only to succumb to heart failure in as little as five years. One such targeted 
therapy is the small molecular receptor tyrosine kinase sunitinib. Sunitinib was developed in 
the early 2000’s as part of a wave of antiangiogenic drugs that target the vascular 
endothelial growth factor receptors and platelet-derived growth factor receptors. 
Unfortunately, up to 47% of patients treated with sunitinib develop severe hypertension and 
approximately 20% develop cardiac dysfunction. The aim of my dissertation is therefore 
twofold: First, to identify the mechanism of sunitinib-induced cardiotoxicity in order to 
develop strategies to prevent clinical cardiotoxicity and, secondly, to use this mechanistic 
insight as a discovery platform to identify new targets for the treatment of human heart 
failure. My work led to the discovery that coronary microvascular pericytes are a primary 
target of sunitinib. Furthermore, co-treatment with thalidomide can protect from sunitinib-
induced cardiac dysfunction without altering the antitumor effect of the drug. Examination of 
sunitinib-induced metabolic changes revealed that sunitinib treatment leads to a profound 
increase in glucose uptake in the heart and induction of the M2 isoform of pyruvate kinase. 
Collectively, my work suggests that vessel normalization and the Warburg Effect may be 
novel targets for the treatment of human heart failure.  
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LAY SUMMARY 
 When one thinks of the side effects of chemotherapy, hair loss and nausea 
commonly come to mind. However, a much less recognized—yet grave—side effect of 
certain chemotherapies is heart failure. This is because newer treatment options have vastly 
improved survival, making post-cancer quality of life much more relevant. The development 
of cardiac dysfunction while receiving cancer treatment is exacerbated by the fact that a 
growing number of patients have significant cardiovascular risk factors—such as obesity, 
diabetes or smoking—at the time of diagnosis.  Nonetheless, a patient may outlive his or her 
cancer only to succumb to heart failure in as little as five years.  Sunitinib is one such 
chemotherapy. Primarily used to inhibit blood vessel growth in tumors, sunitinib causes a 
severe increase in blood pressure in up to 47% of patients and causes cardiac dysfunction 
in another 20% of patients. The aim of my dissertation is therefore twofold: First, to develop 
strategies to prevent heart failure in patients receiving sunitinib and, secondly, to use what I 
learn about how sunitinib affects the heart to identify new strategies to treat human heart 
failure. My work led to the discovery that sunitinib disrupts the stability of blood vessels in 
the heart. Furthermore, this vascular instability can be prevented by co-treatment with the 
drug thalidomide. Further work revealed that sunitinib treatment leads to increased uptake of 
sugar by the heart and alters the way it is broken down into fuel. My results suggest that 
these changes may lead to a thickening of the walls of the heart and subsequent heart 
failure. Collectively, my work demonstrates that blood vessel stability and the utilization of 
sugar may be novel targets for the treatment of human heart failure. 
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Chapter 1           
INTRODUCTION 
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1. Introduction 
This dissertation addresses structural, functional and metabolic features of cardiotoxicity 
of the chemotherapeutic receptor tyrosine kinase inhibitor, sunitinib. Using this compound as 
a discovery platform for cellular mechanisms of heart failure my work has also resulted in 
new insights into microvascular stability and metabolic features of the failing human heart.  
 
1.1 Cardiotoxicity of Chemotherapeutic Agents 
Cardiotoxicity is a frequent consequence of cancer chemotherapy. However, a 
suitable definition of the term is lacking. The term cardiotoxicity includes direct effects on the 
myocardium, myocardial ischemia, arrhythmias, thromboembolisms, inflammation of the 
myocardium (myocarditis), and pericardium (pericarditis) as well as alterations in 
hemodynamic parameters such as hypertension, acute coronary syndrome, and coronary 
vasospasms. These effects can manifest acutely during treatment or occur many years after 
treatment as a result of undiagnosed or subclinical cardiovascular dysfunction. Although 
likely driven by vastly different mechanisms, the management of chemotherapy-induced 
cardiotoxicity is no different from the management of heart failure in general. For instance, 
there are no established guidelines for the specific management of chemotherapy-induced 
cardiotoxicity. Physicians rely on the New York Heart Association Functional Classification 
and on standard modes of treatment (e.g. beta-blockers, ACE inhibitors, and calcium 
channel blockers) (Figure 1.1).  
Building on previous work by Michael Schneider on c-myc signaling in the failing 
heart, Hoshijima and Chien detailed the strong parallels between signaling pathways that 
drive cancer growth and cardiac hypertrophy (Cheng and Force, 2010; Hoshijima and 
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Chien, 2002; Mulvagh et al., 1988) Based on this reasoning it should come as no surprise 
that many chemotherapeutics are also toxic to the heart. 
Cardiotoxicity due to cancer chemotherapeutics is not a new phenomenon.  The 
cardiotoxic effects of Adriamycin® (doxorubicin), a general DNA intercalating agent, were 
described even before the drug gained FDA approval in 1974.  However, it was thought that 
with the development of more targeted therapies, the prevalence of cardiotoxicity would 
diminish.  It was therefore a surprise when significant cardiotoxicities were identified with 
modern agents. Cardio-Oncology (or Onco-Cardiology depending on the source) has 
emerged as a new discipline with a focus on patients who develop heart failure while 
undergoing cancer treatment. The primary reason for this new subspecialty is simple: along 
with improving survival rates comes an increased focus on post-cancer quality of life. This is 
accompanied by soaring rates of cardiovascular disease, diabetes and obesity in the 
general population, significantly increasing the risk of a cancer patient developing 
cardiovascular dysfunction while on treatment. Outside of major cancer treatment centers, 
the underlying cardiac dysfunction is not often recognized until much later, owing to the fact 
that common signs of heart failure: fatigue, dyspnea and even cachexia, are commonly 
present in the cancer patient. New drugs may also not carry adequate warnings that would 
aid the oncologist in recognizing symptoms..  
Cardiotoxicity is often not wholly predicted by preclinical and clinical trials. This is 
primarily because patients with existing cardiovascular disease, or those with risk factors 
such as hypertension or coronary artery disease, are often excluded from early trials. 
Additionally, routine cardiac monitoring and identification of cardiovascular endpoints are 
rarely part of the trial protocol. The exception is when there is precedent of cardiotoxicity in  
  
 Figure 1.1 
 
Figure 1.1. New York Heart Association Classification of Heart Failure. 
[Source: American Heart Association. “Classes of 
http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes
Heart-Failure_UCM_306328_Article.jsp
 
Heart Failure.” 2014. 
.] 
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Table 1.1. 
Phase Objective Goals 
  
Phase I 
 
Safety 
• 20-80 healthy volunteers 
 
• Determine frequent side effects 
 
• Drug metabolism and excretion 
 
 
Phase II 
 
Effectiveness 
• 100’s of patients 
 
• Determine if the drug works for a certain 
disease or condition compared to standard 
treatment/placebo 
 
• Safety and side effects continue to be 
monitored 
 
 
 Phase III 
 
Safety and 
Effectiveness 
• 1000’s of patients 
 
• Studied in different populations at different 
doses 
 
• Study uses of the drug in combination with 
other drugs 
 
 
New Drug 
Review by FDA 
 
Approval 
• Evaluate the quality of the data 
 
• Determine labeling and marketing 
 
• FDA will inspect facilities where drug will be 
manufactured 
 
 
 Phase IV 
 
Continued 
safety 
• Monitor post-marketing safety in the larger 
population 
 
• Sponsor is required to submit periodic safety 
updates to the FDA. 
 
 
Table 1.1. Classification of Clinical Trials. Clinical trials are stratified based on the goal of 
the study with drug safety always being the primary concern. [Source: “US Food and Drug 
Administration Drug Approval Process.” Food and Drug Administration website 
www.fda.gov.]
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similar drugs in a class, such as the receptor tyrosine kinase inhibitors. In this case, the FDA 
may mandate assessment of cardiac function in these patients. Furthermore clinical trials—
even large phase III trials (see Table 1.1 for classification of clinical trials)—are not always 
sufficiently sized to identify less common toxicities (Hawthorne, 2010). For instance if the 
rate of cardiotoxicity occurs at 1 in 1000 patients and, on average, a drug is tested in a few 
thousand patients before approval, there will not be a strong enough correlation to identify 
the toxicity. Thus significant cardiotoxicity is often not recognized until the drug is available 
to the larger population (i.e. after marketing of the new drug).   
1.2 Classes of Cardiotoxic Agents 
Several different types of cancer treatments cause cardiac dysfunction. Therefore, a 
brief review of these agents and their effects on the heart is in order. 
1.2.1 Anthracyclines 
The group of anthracyclines continues to account for the majority of chemotherapy-
induced cardiotoxicity. Adriamycin® (doxorubicin), a general DNA intercalating agent, 
induces oxidative damage and cardiomyocyte necrosis in a dose-dependent and cumulative 
manner. The mechanism of doxorubicin-induced cardiac damage is now relatively well 
understood and is likely due to the generation of reactive oxygen species and 
cardiomyocyte apoptosis (Zhou et al., 2001b). Anthracyclines may also target 
topoisomerase II (Top2)-dependent DNA binding in both the cardiomyocyte nucleus and 
mitochondria (Zhang et al., 2012). Co-treatment with dexrazoxane, an EDTA-like iron 
chelator, has proven to be an effective strategy for limiting ROS damage and cardiotoxicity 
in patients receiving low-dose doxorubicin (Hasinoff et al., 2003; Swain et al., 1997). 
However, dexrazoxane can interfere with the drug’s oncologic efficacy, and therefore since 
2011 its use has been limited to breast cancer patients receiving high-dose doxorubicin 
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(Edvardsen and Sarvari, 2013). Nonetheless, doxorubicin remains a widely used treatment 
option, particularly for pediatric lymphoma patients.  
1.2.2 Her2/neu Inhibitors 
 Mutations in the ErbB2/Her2 receptor are common drivers of cell growth and 
proliferation, most notably in ErbB2/Her2-positive breast cancer.  Patients treated with 
trastuzumab (Herceptin®), a monoclonal antibody directed against the ErbB2 receptor, are 
at significantly higher risk of cardiotoxicity, particularly if previously or co-treated with an 
anthracycline (Hahn et al., 2014). Her2 receptors are also expressed in the heart. Our lab 
has found upregulation of the receptor in the failing heart, which is partially reversible with 
mechanical unloading (Uray et al., 2002). Neuregulin (NRG-1) signaling through the Her2 
receptor to ErbB4 regulates an essential pro-survival pathway that mediates the heart’s 
response to pressure overload stress (Sawyer et al., 2002; Zhao et al., 1998). For this 
reason, angiotensin converting enzyme (ACE) inhibitors are effective in minimizing 
trastuzumab cardiotoxicity (Mackey et al., 2008). Limited evidence also suggests that 
moderate exercise can improve cardiac function in these patients (Jones and Alfano, 2013; 
Scott et al., 2011).  
1.2.3 Receptor tyrosine Kinase Inhibitors 
 Since Judah Folkman’s 1971 discovery of TAF (tumor angiogenesis factor), a pro-
angiogenic factor isolated from tumor cells, the field of tumor angiogenesis, and the 
development of antiangiogenic cancer therapies, has rapidly evolved (Folkman, 1971).  The 
first milestone was reached in 2004 when the FDA approved bevacizumab (Avastin®, 
Genentech), a monoclonal antibody directed against the proagniogenic vascular endothelial 
growth factor (VEGF).  The success of this drug in blocking angiogenesis in several solid 
tumor types—including metastatic colorectal cancer, and non-small cell lung cancer—led to 
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the rapid FDA approval of two subsequent small molecule receptor tyrosine kinase inhibitors 
(RTKIs): sorafenib (Nexavar®, Bayer Pharmaceuticals), in December of 2005, and sunitinib 
(Sutent®, Pfizer) in January of 2006 (Rock et al., 2007).  In addition to targeting the VEGFR, 
these agents also target the platelet-derived growth factor receptors (PDGFRs). Both of 
these agents are approved for use in metastatic renal cell carcinoma, among a group of 
other highly vascularized solid tumors.  Two additional small molecule RTKIs have been 
developed and are now in different stages of clinical trials: axitinib (AG013736, Pfizer) and 
pazopanib (Votrient®, GlaxoSmithKline).  
 The principle behind antiangiogenic treatment is to cut off blood supply to the tumor, 
thereby inducing nutrient deprivation and limiting the potential for cell evasion and 
metastasis. This is accomplished through three main mechanisms: regression of existing 
vasculature, normalization of blood vessels and inhibition of the formation of new vessels 
(Rini, 2007). Angiogenesis is driven primarily by the VEGF receptor, PDGFRβ, fms-related 
tyrosine kinase 3 (FLT3) and the stem cell factor KIT. While FLT3 and KIT may contribute to 
blood vessel growth, the antiangiogenic properties of these drugs are conferred primarily 
through inhibition of the VEGFR on endothelial cells and the PDGFRβ on pericytes (Rini, 
2007).  While originally touted as the next revolution in cancer treatment, the promise of 
antiangiogenic drugs has been somewhat disappointing. Some patients do not respond at 
all whereas others rapidly develop resistance (Rapisarda and Melillo, 2012). Furthermore, 
the increase in survival has been relatively modest in those who do respond.  
1.3 Current Methods of Diagnosis and Treatment  
Similar to non-cancer related heart failure, cardiotoxicity is usually first recognized by 
a significant decrease in left-ventricular ejection fraction or fractional shortening when 
assessed by echocardiography or cardiac magnetic resonance imaging. Cardiac 
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arrhythmias may also be present on the electrocardiogram. Elevated circulating levels of 
cardiac troponins or naturietic peptides are also indicative of cardiac damage and are also 
used as biomarkers of cardiotoxicity in cancer patients (Cardinale et al., 2004; Dolci et al., 
2008).  Increasingly, routine cardiac monitoring is included for patients receiving known 
cardiotoxic agents, especially if there are risk factors or a family history of cardiovascular 
disease. 
When clinically significant cardiotoxicity is identified in a patient, an otherwise 
effective cytostatic treatment must be stopped and the cardiac dysfunction addressed before 
the patient either resumes treatment or switches to an alternative treatment. Management of 
chemotherapy-induced cardiotoxicity is no different from treatment of standard cardiac 
patients, including the usual combination of ACE inhibitors, beta-blockers and diuretics. Two 
recent studies found that prophylactic treatment with the ACE inhibitor enalapril or the beta-
blocker carvedilol helped mitigate cardiotoxicity associated with anthracycline (doxorubicin) 
treatment (Lipshultz et al., 2002; Santos et al., 2002). Longer drug infusion times have also 
been shown to decrease cardiotoxicity but require the use of infusion pumps and indwelling 
catheters (Ewer et al., 2005). Most patients who receive proper cardiac care will recover 
cardiac function. However, approximately 8% of patients who develop heart failure do not 
survive past 10 years (Cheng and Force, 2010).  
1.4 Sunitinib 
1.4.1 Discovery and Development 
Shortly after Dr. Folkman’s discovery of TAF, a number of companies developed 
ATP analogs that could compete with ATP for the catalytic site on most tyrosine kinases. 
This research led to the develoment of receptor tyrosine kinase inhibitors, including 
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Gleevec® (imatinib), Tarceva® (erlotinib) and Sutent® (sunitinib), all of which are in current 
clinical use. 
Sunitinib (SU11248) was developed by Schlessinger and Ullrich who formed 
SUGEN, a biotechnology company which was bought by Pharmacia and subsequently by 
Pfizer (Faivre et al., 2007). After undergoing multiple iterations of the chemical due to low 
solubility and high toxicity, SU11248 showed antitumor efficacy in both cell and animal 
studies. Ensuing phase I trials in patients with acute myeloid leukemia and solid tumors 
established a dose of 50mg per day on a 4 weeks on, 2 weeks off, cycle schedule. This was 
primarily to avoid bone marrow and adrenal toxicity (Faivre et al., 2007). Phase I trials also 
revealed specific efficacy for the treatment of imatinib resistant gastrointestinal stromal 
tumors (GIST) and metastatic renal cell carcinoma (mRCC). Sunitinib treatment of mRCC in 
Phase II trials resulted in an objective response rate (ORR) of approximately 42%. This was 
far superior to the existing therapy for mRCC, interferon alpha (INFα), which had an average 
ORR of less than 20% (Faivre et al., 2007). Thus sunitinib was first approved for, and is still 
predominantly used for, the treatment of mRCC. Cardiotoxicity associated with sunitinib 
treatment was not recognized until later Phase III trials. 
Approximately 60% of mRCC tumors have mutations in the tumor suppressor, von 
Hippel-Lindau (VHL) (Rini et al., 2009). VHL is an E3 ligase that under normoxic conditions 
binds to hydroxylated proline residues in the alpha subunit of hypoxia inducible factor 1 
alpha (Hif1α), thereby targeting it for degradation by the proteasome. When intracellular 
oxygen levels fall, VHL dissociates from Hif1α, allowing it to dimerize with Hif1β and induce 
transcription of a multitude of genes, including VEGF and PDGF. Accordingly, VHL 
mutations in mRCC result in a strong induction of angiogenesis and highly vascularized 
solid tumors. The most common clinical manifestation of VHL syndrome is angioblastoma. 
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Over 1500 germline or somatic mutations have been described in VHL disease, which is an 
autosomal dominant disease occurring in 1/100,000 people.  
Sunitinib exhibits strongest affinity for the VEGFR followed closely by the PDGFR, 
Fms-related tyrosine kinase 3 (FLT3) and KIT (Faivre et al., 2007). Sunitinib, however, is an 
extremely promiscuous TKI, owing to the high conservation of the ATP binding pocket 
across the kinome. In an in vitro test, sunitinib inhibited nearly 20% of all kinases tested 
(Rock et al., 2007) and it is estimated that it can inhibit up to 300 different kinases (Force et 
al., 2007). Nonetheless, there is a tendency to develop resistance when used as a single 
treatment and there has been a push to combine sunitinib treatment with other treatments 
(Faivre et al., 2007). This combination therapy may hold promise in limiting sunitinib toxicity 
as the drug could be used at lower doses. 
1.4.2 Clinical Incidence of Cardiotoxicity with Sunitinib. 
In accordance with the National Cancer Institute’s Common Criteria for Adverse 
Events (CCTAE) National Cancer (Institute, 2009), clinical trials report the incidence of 
adverse events in patients receiving a new drug. Adverse events are scored on a scale of 1-
5, with 1 being the least severe (see Table 1.2 for a description of the grading of adverse 
cardiac events in clinical trials). Diarrhea, nausea, fatigue and vomiting are common with 
most chemotherapeutics, but it was the high incidences of hypertension and decline in left-
ventricular ejection fraction (LVEF) that was most striking with sunitinib, though the reported 
incidences of both vary widely (see below). This may be for several reasons including the 
extent of cardiac monitoring and trial exclusion criteria.  
 Table 1.2 National Cancer Institute’s Common Terminology Criteria for Adverse Cardiac Events. 
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Table 1.2.  National Cancer Institute’s Common Terminology Criteria for Adverse 
Institute  (2009). Common Terminology Criteria for Adverse Events V4.0 H.a.H. Services, ed.
Cardiac Events. [Source: National Cancer
 (Institute, 2009)
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In preclinical monkey studies, there was evidence of increased in arterial blood 
pressure and QT intervals at high doses of sunitinib. However, the first indication of 
significant hypertension with sunitinib was reported in a 2006 randomized, double blind 
Phase III trial for sunitinib as a second-line treatment of imatinib-resistant GIST (Demetri et 
al., 2006; Faivre et al., 2007). Of the 202 patients that received sunitinib, 18 patients (8.9%) 
developed hypertension with 3 patients (6%) developing grade 3, which is defined as an 
increase of greater than 20 mmHg (diastolic) or to greater than 150/100 mmHg and 
requiring more than one antihypertensive medication. The major Phase III study that 
supported the FDA approval of sunitinib as a second line treatment for GIST, reported 
hypertension in 31 patients (15%) with 9 patients (4%) developing grade 3/4 (Rock et al., 
2007).  Most relevant for my experimental work was a decline in LVEF to >50% in 11% of 
patients treated with sunitinib versus 3% in the placebo group. Closely following this study, a 
randomized phase III study of sunitinib versus interferon alpha as a first line treatment for 
mRCC reported that 24 patients (8%) developed hypertension and 10 patients (3%) 
developed a decline in LVEF of at least 10% (Motzer et al., 2007).   
With a longer follow-up, Telli et al found a decline in LVEF to below normal levels 
occurred in 21%, with 4% of patients experiencing a drop in LVEF of greater than 20% (Telli 
et al., 2008). This was important because it suggested that a significant portion of patients 
receiving sunitinib experience subclinical cardiotoxicity. In an effort to clarify the incidence of 
hypertension with sunitinib, Zhu and colleagues conducted a meta-analysis of 4,999 mRCC 
patients from 13 different trials and reported the incidence of hypertension to be 21.6% with 
6.8% of patients developing high grade (3 or 4) hypertension (Zhu et al., 2009). Similarly, a 
retrospective, multicenter analysis of 175 patients with mRCC—with a focus on adverse 
cardiac events—found that 17 patients (18.9%) develop some degree of cardiac abnormality 
with 12 patients (6.9%) developing grade 3 or higher left ventricular dysfunction and 
16 
 
congestive heart failure (Di Lorenzo et al., 2009).  Noting the high incidence of cardiotoxicity 
in their own clinic, Telli and colleagues at Stanford University performed a retrospective 
study of 48 patients who had received sunitinib between July 1, 2004 and July 1, 2007 in 
their clinic (Telli et al., 2008). Seven patients (15%) developed symptomatic grade 3/4 heart 
failure and 3 patients had persistent cardiovascular dysfunction despite discontinuation of 
sunitinib and commencement of heart failure treatment. The Telli study is unique in that 
these patients were treated off-protocol, meaning that no patient was excluded because of 
hypertension, coronary artery disease or previous treatment with an anthracycline. 
Therefore Telli’s patient population is more representative of the general population. 
Collectively, the incidence of hypertension with sunitinib is approximately 20% and the 
incidence of LVEF decline is between 7% and 15%.  
The most quoted study of sunitinib cardiotoxicity describes a much higher incidence 
of cardiotoxicity. Chu et al performed a retrospective analysis of a Phase I/II trial of 75 
patients with GIST treated with sunitinib (Chu et al., 2007). Six patients (8%) developed 
congestive heart failure, while 10 patients (28%) and 7 patients (19%) experienced EF 
declines to >10% and >15%, respectively. The authors also report that 35 patients (47%) 
had blood pressures of greater than 150/100 mmHg. In addition to vastly higher incidences 
of cardiovascular toxicity compared to much of the literature, this study is notable because it 
was the first attempt to evaluate the mechanism of sunitinib cardiotoxicity. 
1.4.3 Proposed Mechanisms of Cardiotoxicity  
While the clinical incidence of sunitinib cardiotoxicity has been extensively 
documented, studies investigating the molecular mechanism tend to be descriptive, primarily 
noting cardiomyocyte hypertrophy, cellular ATP depletion and apoptosis (Chu et al., 2007; 
Cohen et al., 2011; French et al., 2010; Kerkela et al., 2009; Korashy et al., 2014; Will et al., 
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2008). In these studies, the mechanism is often broadly attributed to the promiscuity of the 
kinase and the inhibition of a wide range of kinases. In a study using in vitro competition 
binding assay, which screened 38 different compounds against 317 different kinases (~55% 
of the predicted human kinome), sunitinib inhibited 57% of all kinases tested (Hasinoff et al., 
2008; Karaman et al., 2008) (Figure 1.2). This was second only to staurosporine, which is 
well known as a non-selective inhibitor. A similar screen found that sunitinib inhibited up to 
147 of the 242 kinases tested (Kumar et al., 2009).  Beyond its primary targets (VEGFR, 
PDGFR, cKIT, FLT3) sunitinib potentially inhibits the metabolic energy regulator, AMP-
activated protein kinase (AMPK) and ribosomal S6 kinase (RSK) (Kerkela et al., 2009; 
Laderoute et al., 2010). Consequentially, most of the investigations into the mechanism of 
sunitinib cardiotoxicity have centered on these two kinases. 
In their pioneering investigation of the molecular mechanism of sunitinib 
cardiotoxicity, Chu and colleagues obtained endomyocardial biopsies from two patients that 
had developed left ventricular dysfunction and congestive heart failure while on sunitinib 
(Chu et al., 2007). Not only was there evidence of cardiomyocyte hypertrophy, but there was 
also aberrantly shaped and swollen mitochondria with effaced cristae and membrane 
“whorls” (Figure 1.3), though it has been suggested this is a freezing artifact (Dr. Michael 
Ewer, MD Anderson Cancer Center, personal communication). The same group 
demonstrated aberrantly shaped mitochondria in mice treated with sunitinib at 40mg/kg for 
21 days. Nonetheless, neonatal rat ventricular myocytes treated with sunitinib at clinically 
relevant concentrations (1uM) displayed increased apoptosis, as evidenced by cytochrome 
c release and caspase 9 activation (Chu et al., 2007). As a follow-up to this paper, the same 
group treated mice for 5 weeks at a dose of 25mg/kg (Kerkela et al., 2009). Histological 
assessment of cardiomyocyte size revealed cardiomyocyte hypertrophy despite no 
difference in left ventricular mass. This, the  
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Figure 1.2. 
 
 
 
Figure 1.2. Selectivity profiles of receptor tyrosine kinase inhibitors.  
The sizes of the red circle represent the affinity of binding for the inhibitor to a given kinase. 
The smallest circle represents a Kd of 10 µM and 1 nM for the largest circle.  The tyrosine 
kinases are depicted in the upper left of the graph. Sunitinib is the most non-specific kinase 
inhibitor behind staurosporine. [Source: Karaman, M.W., Herrgard, S., Treiber, D.K., Gallant, 
P., Atteridge, C.E., Campbell, B.T., Chan, K.W., Ciceri, P., Davis, M.I., and Edeen, P.T. 
(2008). A Quantitative Analysis of Kinase Inhibitor Selectivity. Nature biotechnology 26, 127-
132. (Karaman et al., 2008). Used with permission from the journal, license number 
3583190938523.] 
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Figure 1.3 
 
 
 
 
Figure 1.3. Sunitinib-induced mitochondrial structural abnormalities.  
Endomyocardial biopsies from two patients who developed heart failure while on sunitinib 
demonstrating aberrantly shaped and swollen mitochondria with effaced cristae and 
membrane “whorls.” [Source: Figure 5 from Chu, T.F., Rupnick, M.A., Kerkela, R., 
Dallabrida, S.M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., and 
Desai, J. (2007). Cardiotoxicity Associated with Tyrosine Kinase Inhibitor Sunitinib. The 
Lancet 370, 2011-2019. (Chu et al., 2007) Used with permission from the journal, license 
number 3583200430074.] 
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authors concluded, was consistent with myocyte loss, and went on to show evidence of 
apoptosis in NRVMs. The authors also observed a loss of mitochondrial membrane potential 
and depletion of cellular ATP content. However, mitochondrial respiration was not 
measured. ATP content does not reflect the rate of ATP turnover (Taegtmeyer et al., 1985). 
Consistent with the theory that sunitinib inhibits AMPK, the decline in cellular ATP levels did 
not result in a corresponding activation of AMPK, as measured by phosphorylation of its 
downstream target acetyl-CoA carboxylase (ACC). Furthermore, restoration of AMPK 
signaling with adenoviral transfection of constitutively active AMPK reduced sunitinib-
induced cell death.  
Nonetheless, inhibition of AMPK as the cause of sunitinib cardiotoxicity remains a 
debated issue.  Activation of AMPK using the biguanide metformin did not protect from 
sunitinib-induced cell death in NRVMs (Hasinoff et al., 2008). The same authors 
demonstrated that ROS-mediated cell death was also not likely the cause of cardiotoxicity, 
because dexrazoxane also did not prevent sunitinib-induced cell death. Pretreatment of 
human induced pluripotent stem-cell derived cardiomyocytes with metformin or AICAR, a 
similar AMPK activator, also did not protect from sunitinib-induced cell death (Cohen et al., 
2011). As an alternative cause of sunitinib-induced energy depletion, others have tested 
whether sunitinib affects mitochondrial ATP generation. Of four small-molecule receptor 
tyrosine kinase inhibitors tested (imatinib, dasatinib, sunitinib and sorafenib), only sorafenib 
significantly affected respiration of isolated mitochondria from H9C2 cardiomyocytes (Will et 
al., 2008). In particular, sunitinib lacked any direct mitochondrial effects. Still, others have 
observed the appearance of autophagic vesicles and increased autophagic flux both in vivo 
and in vitro (Knapton et al., 2013; Zhao et al., 2010). Collectively, these studies support the 
notion that sunitinib treatment results in cardiac energy depletion, yet the exact mechanism 
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remains to be determined. My work suggests that hypoxia plays role and is discussed in 
detail in Chapter 4.  
1.5 Cardiotoxicity as a Discovery Platform for Cellular Mechanisms of Heart 
Failure. 
Most of clinical cardiotoxicity research is centered on the development of biomarkers 
for earlier identification of cardiac dysfunction as well as advancing methods of cardiac 
imaging (strain-gauge echocardiography, 3D echocardiography). There is also a broad push 
for increased cardiac monitoring and longer follow-up times in patients receiving known 
cardiotoxic drugs. Because of the delayed cardiotoxic effects of certain chemotherapeutic 
agents (Hahn et al., 2014), there has also been a call for the establishment of patient 
registries to allow for easier identification of cardiotoxic therapies post-FDA approval (Cheng 
and Force, 2010).  Targeted delivery of therapies directly to the cancer cells through new 
technologies such as nanoparticles or dual-specific antibodies may also decrease 
cardiotoxicity in the future.  As discussed above, comparatively little research has 
investigated the molecular mechanisms of cardiotoxicity, with the exception of doxorubicin. 
Ideally, once the mechanism by which a treatment causes cardiac dysfunction is known, 
adjunct therapies can be developed to protect the heart while still killing the cancer.  
To this end, my first mentor Dr. Aarif Khakoo (now of AMGEN in South San 
Francisco, CA) developed the concept of “cardiotoxicity as a discovery platform” (Figure 
1.4). His idea was that once significant cardiotoxicity is associated with a particular new 
therapy—such as sunitinib—the drug can be taken into animal studies for target 
identification and mechanistic insight. This mechanistic insight can be used to identify novel 
targets for the treatment of non-chemotherapy related human heart failure. I propose to 
extend the concept of “cardiotoxicity as a discovery platform” to a discovery platform for the 
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identification of cellular mechanisms and metabolic derangements in heart failure. Until the 
work of my previous lab, PDGFRβ signaling and the presence of pericytes in the coronary 
microvasculature was thought to be unimportant in the adult heart. As it will be 
demonstrated in Chapter 3, PDGFRβ signaling within the pericyte is essential for the ability 
of the heart to respond to stress. Increasing pericyte coverage in the failing heart may be a 
novel treatment strategy for heart failure. Furthermore, as it will be demonstrated in Chapter 
4, my experiments in rodents have exposed a major metabolic signaling pathway in failing 
human hearts which is akin to the Warburg Effect in cancer.  
  
 Figure 1.4. 
 
 
Figure 1.4. Cardiotoxicity as a Discovery Platform. 
toxicities are identified in early clinical trials or post
a mouse model for target identification and mechanistic insight. The findings can be used in 
one of two ways. The first is to identify strategies to prevent and predict cardiotoxicity in the 
cancer patient. The second is to identify possible novel targets for the treatment of non
chemotherapy related human heart failure. 
Discovery Platform.” Personal communication.
After significant cardiovascular 
-approval trails, the drug can be studies in 
[Source: Khakoo, A. “Cardiotoxicity as a 
]
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Chapter 2           
MATERIALS and METHODS 
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2.1 Materials 
2.1.1 Animals 
 Animals were cared for according to the National Institutes of Health guidelines. All 
protocols were approved by The University of Texas MD Anderson Cancer Center 
Institutional Animal Care and Use Committee or the Animal Welfare Committee of The 
University of Texas Health Science Center at Houston. The hyperinsulinemic euglycemic 
clamp procedures were approved by the Institutional Animal Care and Use Committee of 
Baylor College of Medicine (Houston, TX). All mice were of C57BL/6J background and 
obtained from Jackson Labs with the exception of immunodeficient nude mice used for the 
in vivo tumor xenograft experiments.  
In vivo tumor xenograft experiments. Immunodeficient nude mice (NU/J) were 
obtained from Jackson Laboratories. A sunitinib-sensitive, human-derived renal cell 
carcinoma cell line (786-0) was obtained from Dr. Eric Jonasch at the MD Anderson Cancer 
Center. Cells (107 ) were suspended in 150 ml of PBS, mixed with an equal volume of 
Matrigel (BD Biosciences), and injected subcutaneously into the left flank. Mice were 
euthanized when tumor volume exceeded 1500 mm3. 
2.1.2 Human Heart Muscle Samples 
Tissue Samples from failing hearts: Failing heart muscle samples were obtained 
from patients referred to the Texas Heart Institute with advanced heart failure and implanted 
with a left ventricular assist device (LVAD). Tissue from the left ventricular apex was 
obtained during LVAD implantation and again at the time of device removal by Dr. O. 
Howard Frazier at the Texas Heart Institute (Houston, TX). Tissue samples were 
immediately freeze clamped between two aluminum blocks precooled in liquid nitrogen as 
previously described by Wollenberger et al. (Wollenberger et al., 1960).  Human subjects 
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gave informed consent and the study protocol was approved by the Committee for the 
Protection of Human Subjects of CHI St. Luke’s Health in Houston, Texas, and by The 
University of Texas Medical School at Houston. 
Non-failing Heart Samples: Non-failing heart samples were obtained from the apex of 
the left ventricle of patients undergoing heart-lung transplantation due to pulmonary 
hypertension and right-ventricular failure. Left-ventricular function was normal, as assessed 
by echocardiography. A full characterization of these patients and method of tissue 
harvesting has been published (Cordero-Reyes et al., 2014). This study was approved by 
the Houston Methodist Hospital's Institutional Review Board. 
 
2.1.3 Reagents 
Sunitinib malate obtained from Pfizer for the pericyte experiments and purchased 
from LC Laboratories (St. Louis, MO) for the metabolic experiments Dimethyloxalylglycine 
(DMOG) was obtained from Tocris Bioscience (Bristol, United Kingdom). Cobalt chloride and 
all other laboratory reagents were obtained from Sigma Aldrich (St. Louis, MO). Please refer 
to Table 2.1 for a list of antibodies used in western immunoblotting.  
 
2.2 Methods 
2.2.1 Assessment of Cardiac Function 
 2.2.1.1 Cardiac Magnetic Resonance Imaging 
 Magnetic resonance imaging (MRI) allows for the acquisition of precise, high-
resolution images of the heart. A strong magnetic field aligns the protons (mainly water 
molecules) within a specimen in a single direction. Pulses of radio frequency 
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electromagnetic fields are applied to alter the alignment of the protons relative to the 
magnetic field. The contrast between the heart wall and the ventricle is determined by the 
rate at which the excited atoms return to equilibrium. Next, a Fourier transformation converts 
this signal into an image. MRI is optimized for cardiac imaging by gating the image 
sequences to the electrocardiogram. This allowed for synchronization of the pulses with the 
beating heart, and enabled visualization of cardiac motion and accurate assessment of 
cardiac output (Epstein, 2007).  
 With the assistance of Dr. James Bankson and the Small Animal Imaging Facility at 
M.D. Anderson Cancer Center, a protocol was developed to image mice on a Bruker 7.05-T 
MR scanner (Bruker Biospin MRI, Billerica, MA). Mice were lightly anesthetized (1-2% 
inhaled isoflurane) and the flow was adjusted to maintain the heart rate between 350-500 
beats per minute and the rate of respiration at 30-40 breaths per minute. Mice were kept 
warm (37oC) by a circulating water-filled imaging platform. Sagittal and coronal images were 
first obtained to orient correctly to the left ventricle and apex of the heart. Next, six (~1mm 
thick) short-axis images were obtained every 6 milliseconds with 3 milliseconds between 
pulses moving from the apex to the base of the heart. The left ventricular chamber size was 
determined in both systole and diastole for each of the six images by tracing the contour of 
the left ventricular and using the modified Simpson’s rule for volume determination (Folland 
et al., 1979). Left ventricular ejection fraction, a measure of systolic function, was defined as 
LVEF = ((EDV – ESV)/EDV)*100 and averaged across the six sections.   
 
2.2.1.2 Coronary Flow Reserve 
 Doppler ultrasound is an proven non-invasive method for determining blood flow in 
the heart and major vessels in the mouse (Hartley et al., 2011; Hartley et al., 2008). Blood 
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flow velocity is determined as the difference in wave frequency between and emitted signal 
and the returning echoes from moving red blood cells. The Doppler signal is the summation 
of Doppler shifted echoes from different red blood cells moving at different velocities. 
Doppler shift frequency (∆f) is related to blood flow velocity (V) by the following equation: 
∆f = 2fo (V / c) cosθ   
Where fo is the ultrasonic frequency (20 MHz for use in mice), c is the speed of 
sound in blood (∼1,540 m/s), and θ is the angle between the sound beam and the direction 
of flow. When the sound beam is parallel to the direction of flow (θ is zero), the conversion 
factor relating velocity to the Doppler shift is 3.75 (cm/s)/kHz at 20 MHz (Hartley et al., 
2011). 
Blood flow velocity through the left descending coronary artery was measured using 
a 2mm diameter 20-Mhz ultrasound probe connected to a signal processing unit 
(MouseDoppler, Indus Instruments, Webster, TX). The animal was lightly anesthetized and 
placed in the supine position on a warmed (37oC) procedure board containing ECG 
electrodes. The ultrasound tip was stabilized and maneuvered using a micromanipulator 
(model MM3-3, World Precision Instruments, Sarasota, FL) until the characteristic LAD 
Doppler signal was obtained. Coronary flow velocities were determined at baseline (1% 
isoflurane) and after application of a hyperemic stimulus (2.5% isoflurane). The vasodilatory 
properties of isoflurane are well described and provide an advantage over adenosine in that 
isoflurane has a smaller effect on heart rate (Hartley et al., 2011). The ratio of peak flow 
velocities at baseline and 2.5% isoflurane is reported as the coronary flow reserve.  
 
2.2.1.3 Mean Arterial Pressure 
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 Mouse blood pressure was measured non-invasively with a specialized tail pressure 
transducer and occlusion cuff (CODA, Kent Scientific, Torrington, CT). This specialized cuff 
directly measures blood volume in the tail (Feng et al., 2008). Non-anesthetized mice were 
placed into nose cone holders and the sensor and occlusion cuff were slid onto the tail. This 
was repeated on three consecutive days before the start of the experiment to allow for 
acclimatization. During a given session, 10 acclimatization cycles were taken followed by 20 
measurement cycles for each mouse. The system measured a total of 6 blood pressure 
parameters simultaneously: systolic blood pressure, diastolic blood pressure, mean arterial 
blood pressure, heart pulse rate, tail blood volume and tail blood flow (Malkoff, 2005).  
 
2.2.1.4 Cardiac Contractile Reserve (dP/dtmax) 
 The ventricular pressure-volume (PV) loop relates changes in ventricular volume to 
pressure throughout the cardiac cycle (Lilly and School, 1998). A PV loop begins at the 
beginning of the cardiac cycle, point a, at the lower left of the loop (Figure 2.1). The point 
represents the opening of the mitral valve and the beginning of ventricular filling in diastole. 
A small rise in pressure is seen when travelling from point a to point b and the ventricle 
stretches in accordance with the properties of passive elastic compliance. Point b is reached 
when this pressure exceeds a, causing the mitral valve to close and isometric left ventricular 
contraction commences. This isometric contraction occurs as the volume remains constant 
as the pressure rises. When the pressure in the left ventricle surpasses the diastolic 
pressure in the aorta, the aortic valve opens and the ventricle begins to empty (point c). The 
pressure continues to increase until the ventricle relaxes.  The curve from point c to d 
represents the afterload, the pressure against which the left ventricle ejects. As the left 
ventricle beings to relax (point d) the pressure in the left ventricle falls and no more blood is 
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ejected from the heart. Isovolumetric relaxation will continue until the pressure in the left 
ventricle drops below the pressure in the left atrium when the mitral valve opens and the 
loop begins again at point a. Changes in cardiac contractility are represented by the slope of 
the end-systolic pressure volume relation (EDPVR) curve. When cardiac contractility is 
increased, such as by the infusion an inotropic agent such as of dobutamine (see Figure 
2.1), this curve shifts upward and to the left (from 1 to 2). As a result, the stroke volume 
increases and the end systolic volume decreases. When there is a defect in cardiac 
contractility, such as I have observed in sunitinib-treated mice, this curve does not shift as 
far, resulting in a decreased slope (Lilly and School, 1998). These experiments were 
expertly performed by Vishnu Chintalgattu with assistance from me.  
For the measurement of cardiac contractility, maximum pressure in the left ventricle 
over time was measured by inserting a pressure sensitive catheter (1 French, Millar 
Instruments, Houston, TX) into the left ventricle. Mice were deeply anesthetized with 
isoflurane and fixed to a heated (37oC) procedure board containing ECG electrodes. Mice 
were intubated, ventilated and a cervical incision exposed the trachea and carotid arteries. 
The catheter was inserted into the left carotid artery and advanced into the left ventricle.  
After stabilization of the heart rate and left ventricular pressures, pressure-volume loops 
were generated using the Millar Pressure-Volume Loop System (Millar Inc. Houston TX). PV 
loops were generated at baseline and with increasing concentrations of dobutamine (1, 3 
and 5 mg/kg per minutes) administered through the tail vein using a syringe infusion pump.  
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Figure 2.1. 
 
Figure 2.1. Left-ventricular Pressure-Volume Loop. A plot of the ventricular pressure as a 
function of volume, over the course of the cardiac cycle. See text for a full description of the 
cycle. ESPVR, end-systolic pressure-volume relation. [Source: Lilly, L.S., and School, H.M. 
(1998). Pathophysiology of Heart Disease: A Collaborative Project of Medical Students and 
Faculty. (Williams & Wilkins). (Lilly and School, 1998)]. 
  
a 
b 
c 
d 
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2.2.1.5. Wire Myography of Isolated Aortic Rings 
Vascular reactivity of isolated aortic rings from mice treated with sunitinib or vehicle 
was performed in a blinded fashion by the lab of Dr. Nathan Bryan at The University of 
Texas Institute of Molecular Medicine as previously described (Erez et al., 2011). 
 
2.2.2 Hyperinsulinemic Euglycemic Clamp* 
 *This procedure was performed by Dr. Pradip Saha of the Mouse Metabolism Core 
at Baylor College of Medicine.  
 The hyperinsulinemic euglycemic clamp procedure was first developed by DeFronzo 
and colleagues in 1979 and has since become the gold standard for assessing whole-body 
glucose homeostasis and insulin sensitivity in both the lab and the clinic (Defronzo et al., 
1979). During this procedure, relatively high blood insulin levels are maintained in order to 
suppress hepatic gluconeogenesis such that a steady-state condition is reached where the 
infusion of exogenous glucose is equivalent to the rate of whole-body glucose disposal 
(GDR) (Tam et al., 2012). The GDR is directly correlated with insulin sensitivity such that a 
high GDR indicates increased insulin sensitivity.  
Five days before the procedure, mice were anesthetized using Nembutal (1ul/g body 
weight)/ avertine (15ul/g of body weight) and a micro catheter was implanted into the jugular 
vein until its tip reached to the right atrium; the catheter was tied with silk sutures at the 
venotomy site. The other end of the catheter was tunneled subcutaneously around the side 
of the neck to the top of the skull where it was exteriorized through skin filled with sterile 
EDTA (0.45%) solution and closed the open end of the catheter using a hot metallic surface. 
On the day of the procedure fasted (overnight), conscious mice were infused with insulin at 
33 
 
a constant rate for 5 hours. Blood samples were collected from tail vein before infusion and 
at every hour during infusion. Mice first received a primed (10uCi) and then constant rate 
intravenous infusion (0.1uCi/min) of HPLC purified [3-3H] glucose for 5 hours using a syringe 
infusion pump. After 60 minutes, mice were infused with 25-50% unlabeled glucose with 
another infusion pump at a rate adjusted to maintain the blood glucose level at 100-140 
mg/dl.  For tissue specific uptake, a 2-deoxy-D-[14C] glucose (2DG) (10uCi) bolus was 
injected 45min before the end of the clamp procedure and a blood sample was collected at 
the administration of 2DG. 2DG is taken up by the cell and rapidly phosphorylated by 
hexokinase but not metabolized further. At the end of the procedure mice were sacrificed 
and tissues were evaluated for radiolabeled 2DG content by liquid scintillation counting.  
Liquid scintillation counting is the standard method to determine the radioactivity of a 
sample. The energy emitted from low-energy radioisotopes is converted to light by the liquid 
scintillation cocktail. This cocktail contains two main components, an organic solvent and a 
scintillator(s) or fluor. The energy released from the radioactive decay excites the scintillator 
which a light pulse. This light pulse is then captured by the scintillation counter’s 
photomultiplier tube and counted (Bray, 1960).  
 
2.2.3 Isolated Cells 
 2.2.2.1 In Vitro Cell Proliferation (MTT) Assay 
 Human placental pericytes (PromoCell, Heidelberg, Germany), human umbilical vein 
endothelial cells (Genlantis, San Diego, CA) and human cardiac fibroblasts (Cell Systems 
Corporation, Kirkland, WA) were serum starved for 6 hours followed by treatment with 
sunitinib for 24 hours. Cell proliferation was measured using an MTT assay kit (Vybrant 
MTT, Life Technologies, Grand Island, NY). A MTT assay is a colorimetric assay that 
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measures cell proliferation by measuring the reduction of the yellow MTT dye (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to its insoluble state, which has a 
purple color. This reduction requires NADH and therefore only occurs in viable, metabolically 
active cells (Fotakis and Timbrell, 2006).  
2.2.3.2 Neonatal Rat Ventricular Myocytes (NRVMs) 
 The protocol for the isolation of neonatal rat ventricular myocytes was adapted from 
a method used by Dr. Diane Bick’s lab at The University of Texas Health Science Center at 
Houston, Department of Pathology (Lash and Jones, 2013). All procedures were carried out 
in a biological safety hood. Neonatal Sprague-Dawley rats (1-2 day old) were briefly washed 
in 70% ethanol and decapitated. The heads were immediately dropped in liquid nitrogen. 
The chest cavity was opened, the heart removed and placed in 1X ADS buffer (NaCl [6.8g], 
KCl [0.4g], glucose [1.0g], NaH2PO4 [1.5g] MgSO4 [0.1g] HEPES [4.76g] and pH adjusted to 
7.38 with HCl/NaOH in 1L total volume of double distilled water [ddH2O]) until all hearts (60 
total) were collected. Hearts were rinsed once with 1X ADS buffer, halved and transferred to 
25mm2 tissue culture flask (15 hearts/flask) containing 9ml of enzyme buffer (1X ADS 
containing pancreatin [0.6mg/mL] and collagenase type II [73U/mL). Flasks were incubated 
for 20 minutes at 37oC in a shaking water bath a total of five times. The supernatant from the 
first step was discarded. The others were collected, centrifuged for 5 minutes at 300g and 
the pellet resuspended in 2-3 newborn calf serum. All fractions were kept in the 37oC 
incubator until the digestion was complete (no visible chunks of heart remaining).   
The pooled pellets were centrifuged for 5 minutes at 300g and resuspended in 4mL 
of Percoll gradient (1.082 g/mL). Percoll gradient tubes were prepared in 15ml Falcon tubes 
using a 15 gauge feeding needle. Gradients were added slowly in order of increasing 
density (1.05 g/mL, 1.062 g/mL, and 1.082 g/mL). Percoll gradients were centrifuged for 20 
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minutes at 300g is a swing bucket rotor a room temperature. The cardiomyocytes remained 
in the 1.802 g/mL layer and were collected and washed 2X with 1x ADS. After the final 
wash, cardiomyocytes were re-suspended in complete media (DMEM [500mL}, BCS [50mL], 
and penicillin/streptomycin [10mL of 100U/mL]). Cardiomyocytes plated at a density of 2 
million cells per 60mm dish (protein) or 0.75 million cells per well in a 6-well plate (RNA). 
The cell culture medium was replaced the next morning and then daily for the remainder of 
the experiment. NRMVs spontaneously contract for up to 7 days in culture.  
 
2.2.3.3 Adult Mouse Cardiomyocytes 
The procedure for the isolation of adult cardiomyocytes (AMCs) was adopted from 
the lab of Paul Simpson (O'connell et al., 2007). The isolation was performed under semi-
sterile conditions; all buffers and equipment were filtered and autoclaved, respectively, 
however hearts were removed and digested outside of the tissue culture hood. 
Mice (6-10 weeks old) were deeply anesthetized with chloral hydrate (60mg/kg) via 
intraperitoneal injection. To avoid clotting in the cardiac vessels, heparin (0.2mL of 
1000U/mL) was injected intraperitoneally. The mouse was deemed fully anesthetized when 
he did not respond to reflex tests (toe or tail pinch). A thoracotomy was performed and the 
beating heart removed by clipping the aorta and pulmonary veins. The heart was 
immediately dropped into ice-cold perfusion buffer (NaCl [120.4mM, KCl [14.7mM], KH2PO4 
[0.6mM], NaHPO4 [0.6mM], MgSO4-7H2O [1.2mM], Na-HEPES [10mM], NaHCO3 [4.6mM], 
taurine [30mM], BDM [10mM], and glucose [5.5mM] in cell culture grade water and pH 
adjusted to 7.0 with HCl). Excess tissue (e.g. thymus) was removed and the aorta teased 
from the surrounding connective tissue. The aorta was cannulated using a 22-gauge 
pediatric catheter cover on a 1mL syringe containing perfusion buffer. The aorta was 
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temporarily fixed onto the cannula using a microclip and the syringe was depressed to 
ensure the heart inflated and there were no leaks from the aorta. The cannula was placed 
on a primed, water-jacketed Langendorff-style apparatus containing warmed (37oC) 
perfusion buffer and tied with silk suture. The heart was perfused in retrograde at 4 
mL/minute for 4 minutes to flush and excess blood from the heart. Next, the buffer was 
switched to perfusion buffer containing collagenase type II (Lot 305, Worthington 
Biochemical, Lakewood, NJ) and CaCl2 [40 µM]. Once the heart became pale and soft (16-
20 minutes) it was cut from the cannula and immediately placed in a 60mm2 dish containing 
2.5mL of stopping buffer (perfusion buffer containing 10% bovine calf serum and 100mM 
CaCl2).  
The heart was teased apart with forceps and pipetted up and down a few times with 
a transfer pipette. The suspension was passed through a cell strainer (100µM), transferred 
to a 15mL Falcon tube and centrifuged at room temperature for 3 minutes at 20g. The 
supernatant was discarded and the pellet resuspended in stopping buffer containing 100µM 
CaCl2. The cells were incubated at room temperature for 2 minutes and next spun again at 
20g for 3 minutes. This was repeated with stopping buffer containing 400µM CaCl2 and 
900µM CaCl2 to gradually restore cellular calcium levels to near physiologic concentrations. 
After the final spin, cells were resuspended in plating medium (MEM [Eagle’s with Hank’s 
Buffered salts] containing 10% bovine calf serum, BDM [10mM], penicillin [100U/mL] and 
ATP [2mM]). Cell density was determined by counting the number of rod-shaped 
cardiomyocytes. The quality of the isolation was determined by the percentage of rod-
shaped, compared to round-shaped cells under an inverted light microscope. At percentage 
of least 50% was considered acceptable for further experimental use. Cardiomyocytes were 
incubated for one hour at 37oC in 2% CO2. Plating medium was then changed to culture 
medium (MEM [Eagles with Hank’s buffered salts], BSA [1mg/mL], penicillin [100U/mL, ITS 
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[insulin (5ug/mL, transferring (5ug/mL) and selenium (5ng/mL)] and BDM [10mM]). 
Experimental procedures began 2 hours after plating.  
 
2.2.4 Tissue Collection and Preservation 
 2.2.4.1 Protein Isolation and Quantification 
 Previously collected tissue was removed from a -80oC freezer and immediately 
placed in liquid nitrogen. Approximately 50mg of tissue was homogenized using a 2mL 
Dounce homogenizer in 1mL of protein lysis buffer (KCl [20mM], HEPES [30mM], EGTA 
[2.5mM], EDTA [2.5mM], β-glycerophosphate [40mM], NaF [40mM], Na4P2O7 [4mM], 
glycerol (10%), Nondiet-40 [0.25%], protease inhibitor [cOmplete Mini tablets, Roche], 
phosphatase inhibitor cocktail 2 and 3 [100µl each/10mL, Sigma]). Samples were 
centrifuged at 14,000xg for 10 minutes at 4oC and the supernatant collected in a new tube 
on ice. For cells, each plate was washed 2x with PBS and 1mL (60mm2 dish) or 100ul/well 
(6-well plate) of protein lysis buffer (NaCl [150mM], HEPES [5mM, pH 7.4], EDTA [0.1mM, 
pH 8.0], MgCl2 [0.1mM], DTT [0.1mM], Triton X-100 [1%], protease inhibitor [cOmplete Mini 
tablets, Roche], phosphatase inhibitor cocktail 2 and 3 [100µl each/10mL, Sigma]) was used 
to scrape the cells from the well. Cells were sonicated and then centrifuged at 14,000xg for 
10 minutes at 4oC.  
 Protein concentration was quantified using a bicinchoninic acid (BCA) colorimetric 
assay (Pierce, Rockford, IL) (Smith et al., 1985). Proteins in an alkaline (biuret reaction) 
solution reduce Cu2+ to Cu+. Two molecules of bicinchoninic acid then chelate with each Cu+ 
ion to form a purple reaction product that is observed at 562nm. The amount of reduced Cu+ 
is proportional to the amount of protein in the sample. This reaction does not have a true 
end point, the color continues to develop, but the reaction is sufficiently slow to allow for 
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accurate assessment of protein concentration. Protein concentration was calculated based 
on a set of BSA standards (12.5-2000 µg/µl). Protein samples were diluted (1:5-1:20) and 
5µl of diluted sample was plated in triplicate in a 96-well plate. The plate was left at room 
temperature for 30 minutes before being read on a plate reader.  
  
2.2.4.2 Nuclear Fractionation 
 Nuclear fractionation was performed on fresh tissue on the day of sacrifice following 
a protocol described by Luo et al (Luo et al., 2011). Fresh tissue or cells were homogenized 
with a Dounce homogenizer in hypotonic buffer (HEPES/KOH [10mM, pH 7.5], KCl [10mM], 
MgCl2 [1.5 mM], K2EDTA [1 mM], EGTA [1 mM], Igepal [0.1%], DTT [1 mM], and protease 
inhibitor [cOmplete Mini tablets, Roche], phosphatase inhibitor cocktail 2 and 3 [100µl 
each/10mL, Sigma]) and left on ice for 30 minutes. Intact cells were removed by 
centrifugation at 53 g for 10 min. The supernatant was then centrifuged at 800xg for 10 min. 
The supernatant was kept as the cytosolic fraction. The nuclear pellet was washed twice 
with hypotonic buffer and lysed in isotonic buffer (hypotonic buffer plus 250 mM sucrose) by 
sonication. Protein concentrations were assessed as described above.  
 
2.2.5 Histology and Immunohistochemistry 
 For histological and immunological examination, hearts were removed from the mice, 
rinsed in ice-cold PBS, cut on the transverse short axis near the apex of the heart. The 
remaining heart was quickly frozen in liquid nitrogen. For paraffin-embedded sections, the 
remaining tissue was placed in 4% paraformaldehyde or optimal cutting temperature 
medium (OCT) and taken to the Histology Research Lab in the UT Department of Pathology 
39 
 
and Laboratory Medicine for processing, embedding and sectioning. Both paraffin-
embedded and frozen tissues were sectioned at 5 microns thick slices.  
  
2.2.5.1 Hematoxylin and Eosin (H&E) Staining 
 H&E staining is the most widely used stain for basic observation of tissue 
morphology. Hematin, the oxidation product of hematoxylin, stains nucleic acids and other 
basophilic features blue through when oxidized in situ with a strong oxidant such as sodium 
iodate (Cardiff et al., 2014). Hematin binds to lysine residues of nuclear histones through a 
metallic ion, usually aluminum. The tissue is oversaturated with the dye to ensure binding 
and the undesirable background staining is then removed by leaching in an alcohol acid 
solution. The blue is then differentiated when returned to an alkaline solution. Next, the 
tissue is stained with eosin which, through a complex and poorly understood mechanism, 
dyes acidic features pink.  
 Paraffin-embedded tissue sections were rehydrated through alcohol gradients to 
distilled water. Sections were then placed in Lillie Mayer’s alum hematoxylin (Sigma Aldrich, 
St. Louis, MO) for 4 minutes, rinsed in running tap water and differentiated in 0.3% acid 
alcohol (350mL ethanol, 125mL ddH2O and 1.5mL concentrated hydrochloric acid) until the 
background was almost colorless. Sections were rinsed in running tap water and then 
Scott’s tap water substitute (2g sodium bicarbonate, 20g magnesium sulfate in 1L ddH2O) to 
differentiate the blue. Next, sections were stained in Eosin-Y (Richard-Allan Scientific) for 2 
minutes, dehydrated, cleared in xylene and mounted. Five random fields from the 
endocardial and epicardial areas of the left ventricle were imaged at 400x using an inverted 
light microscope (Motic AE2000) connected to a 3.0 megapixel camera (Moticam 3). For 
measurement of cardiomyocyte cross-sectional area, round cells (40-60 per heart) 
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displaying clear membrane staining and visible nuclei were traced and area calculated using 
ImageJ software (Abràmoff et al., 2004). 
  
2.2.5.2. Masson Trichrome Staining 
 Masson’s trichrome staining is a three color staining protocol whose primary use in 
cardiology is to determine the extent of collagen deposition in the heart. Paraffin-embedded 
sections were stained using a commercially available kit (Accustain Trichrome Stains, Sigma 
Aldrich, St. Louis, MO). Slides were rehydrated in water and left in Bouin’s solution (Sigma 
Aldrich, St Louis, MO) at room temperature overnight to achieve intense coloration of the 
tissue. Slides were rinsed in running tap water until the yellow color was removed. The 
nuclei were then stained in working Weigert’s Iron Hematoxylin solution (Sigma Aldrich, St. 
Louis, MO) for 5 minutes and rinsed in running tap water followed by ddH2O. Next, slides 
were placed in Biebrich Scarlet-Acid Fuchsin for 5 minutes to stain the cytoplasm and 
muscle fibers red. After rinsing in ddH2O, slides were placed in fresh 
Phosphomolybdic/Phosphotungstic acid for 5-10 minutes to prepare the sections for uptake 
of the Aniline blue stain. Collagen was stained blue in a Aniline blue solution and 
differentiated in 1% acetic acid. Slides were rinsed, dehydrated through alcohol, cleared in 
xylene and mounted.  
  
2.2.5.3 Periodic Acid Schiff (PAS) Staining 
 PAS staining is used to detect glycogen in the heart. Paraffin-embedded tissues 
were rehydrated to water and incubated in periodic acid (0.5%) for 5 minutes. Periodic acid 
is used to oxidize the carbohydrates containing 1-2 glycols, forming aldehyde groups. The 
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slides were then rinsed and placed in Schiff’s reagent (Sigma Aldrich, St. Louis, MO) for 15 
minutes. The aldehyde groups react with Schiff’s reagent to form a deep pink color. Slides 
were rinsed in lukewarm tap water and counterstained with Mayer’s hematoxylin. Slides 
were dehydrated, cleared and mounted. Finished slides were imaged as described above.  
 
 2.2.5.4 Scanning electron microscopy 
 Scanning electron microscopy was performed in a blinded fashion by Dr. Kenneth 
Dunner Jr. in the lab of Dr. Robert Langley at MD Anderson Cancer Center. Briefly, hearts 
were fixed in 2% glutaraldehyde in a 0.1M phosphate buffer (pH 7.4) for 24 hours at 4oC and 
then transported to Dr. Langley’s lab for imaging. Imaging was performed as previously 
described (Higuchi et al., 2000). Images were psuedocolored in Adobe Photoshop. 
Grayscale images were colored with the “hue/saturation” function and the “history brush.” 
 
 2.2.5.5. Immunofluorescence and confocal microscopy 
 Immunofluorescence and confocal imaging of cardiac sections for the assessment of 
microvascular pericyte coverage was performed by Vishnu Chintalgattu. Hearts were fixed in 
10% formalin overnight and then embedded in optimum cutting temperature (OCT) medium. 
Frozen sections were incubated overnight at 4oC with anti-NG2 (1:200, Chemicon 
International) or anti-CD31 (1:200 Phamingen) and then incubated at room temperature with 
a fluorescently labeled secondary antibody followed by DAPI. Sections were imaged with an 
LSM 510 META inverted confocal microscope (Zeiss Instruments). ImageJ was used to 
quantify the NG2 and CD31 coverage area for each image.  
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2.2.5.6. Vessel tortuosity 
 Vessel tortuosity measurements were performed by James Culver, a graduate 
student in the lab of Mary Dickinson at Baylor College of Medicine, who was blinded to the 
treatment groups. Isolated hearts were infused with a 70kDa tetramethylrhodamine-labeled 
dextran (Invitrogen, Waltham, MA) and placed in a 1% agarose gel mold poured into a glass 
bottomed tissue culture dish (MatTek, Ashland, MA). Confocal Z-stacks were acquired 
beginning at the apex of the heart. Images were reconstructed and analyzed with Imaris 
(Bitplane, Oxford Instruments) with custom extensions written by James Culver in MATLAB. 
Vessel tortuosity was calculated for each branch (tortuosity, T, is defined as T = L/D, where 
L is the total arc length along a vessel trace, and D is the total displacement between the 
beginning and end of the branch). 
 
2.2.6 SDS-PAGE and Western Blotting 
 Polyacrylamide gel electrophoresis (PAGE) is used to separate proteins by mass 
and charge. With the addition of the denaturant sodium dodecyl sulfate (SDS), all proteins 
become negatively charged and are separated solely by mass as they migrate through a 
polyacrylamide gel from a negative to positively charged electrode.  Gels were poured in two 
steps, a lower resolving gel and an upper stacking gel. The separation of the proteins is 
dependent of the percentage of acrylamide in the gel. A 10% resolving gel was used for 
most proteins. In rare instances, an 8% resolving gel was used for large proteins (>100 
kDa). For a 10% resolving gel 8mL of lower buffer (8mL lower buffer stock [36.3g Tris-base, 
0.8g SDS, in 200mL of ddH2O, pH adjusted to 8.8], 10.5 mL acrylamide/bis [30%]. 13.4mL 
ddH2O, 300µl ammonium persulfate and 30µl TEMED) was poured between two 1.5mm  
Table 2.1 
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Antibody Molecular 
Weight 
(kDa) 
Manufacturer 
Catalog # 
1o Dilution 2o Type 
(1:5000 dilution 
unless noted) 
GAPDH 37 Fitzgerald 
10R-G109A 
1:50,000 Mouse  
1:10,000 
β-tubulin 55 Santa Cruz 
5274 
1:1000 Mouse 
p-PDGFRβ 190 Santa Cruz 
12909-R 
1:250 Rabbit 
PDGFRβ 190 Cell Signaling 
3169 
1:1000 Rabbit 
NG2 270-300 Millipore 
AB5320 
1:500 Rabbit 
O-GlcNAc 
(CTD110.6) 
37-250 Cell Signaling 
9875 
1:1000 Rabbit 
PKM1 60 Sigma-Aldrich 
SAB 42000094 
1:10,000 Rabbit 
PKM2 60 Cell Signaling 
4053 
1:500 Rabbit 
Hif1α 120 Novus 
NB100-105 
1:500 Mouse 
c-myc 57-65 Cell Signaling 
8492 
1:1000 Rabbit 
Histone H1 34 Santa Cruz 
10806 
1:1000 Rabbit 
Histone H3 18 Santa Cruz 
8654 
1:1000 Goat 
 
Table 2.1 Antibodies used for western blotting.  The address of the manufacturers are as 
follows: Santa Cruz Biotechnology (http://www.scbt.com/) ; Cell Signaling Technology 
(http://www.cellsignal.com); Fitzgerald (http://www.fitzgerald-fii.com/); Millipore 
(www.emdmillipore.com/antibodies); Novus Biologicals (www.novusbio.com).   
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glass plates and allowed to solidify. A layer of isopropanol was floated on top to ensure even 
transition from resolving to stacking gels. Once the gel was solidified, the isopropanol was 
poured off and the stacking gel was added (2.5mL buffer stock [6g Tris-HCl, 0.4g SDS, in 
100mL of ddH2O, pH adjusted to 6.8], 1.5mL acrylamide/bis [30%], 6mL ddH2O, 90µl 
ammonium persulfate and 9µl TEMED). A comb was inserted and the gel was left to solidify 
a room temperature.  
 Protein samples (8-20µg in 5X loading buffer [For 30mL, 3.48g DTT, 9mL glycerol, 
6mL SDS (20%), 7.5mL 1M Tris-HCl (pH 6.0), 2mL bromophenol blue) were boiled to 10 
minutes at 70oC and cooled to room temperature before loading into gels. Gels were run at 
50mV in running buffer (6g Tris-base, 28.8g glycine, 1g SDS in 1L ) until the protein traveled 
through the stacking gel and then turned up to 100mV for the remainder of the run. 
 Separated proteins were transferred to a PVDF (PolyVinyliDene Fluoride) membrane 
using a wet transfer method. PVDF membranes were pre-soaked in methanol (PVDF is 
highly hydrophobic, which makes it ideal for protein binding) and then soaked along with 
sponges and filter paper in cold transfer buffer (100ml of 10x stock [144g Tris-base, 30g 
glycine, 0.5g SDS in ddH2O [1L], 200mL methanol and 700mL ddH2O) until use. After 
completion of the run, gels were soaked in transfer buffer for 10 minutes. A “sandwich” was 
then prepared from the bottom (cathode side) to the top (anode side) with a sponge, filter 
paper, gel, PVDF membrane, filter paper and sponge. The transfer was run in the cold room 
(4oC) for either two hours at 110mV or overnight at 40mV.  
 Following the transfer, membranes were stained with Ponceau to ensure proper 
transfer and then blocked for one hour at room temperature in 5% milk. Membranes were 
incubated overnight in primary antibody (Table 2.1) with gentle rocking. Following 3, 10 
minute washes in 0.4% Tween-TBS (Tris-Buffered Saline) membranes were incubated with 
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a HRP (horseradish peroxidase) conjugated secondary antibody in 5% milk for one hour at 
room temperature. Membranes were washed 3 x 10 minutes and then developed using 
Western Blotting Luminol reagent (Denville Scientific, South Plainfield, NJ). After 
developing, membranes were stripped and re-probed up to three times with stripping buffer 
(6mL Tris-HCl [1M, pH 6.8], 19.2mL SDS [10%], 0.675mL β-mercaptoethanol, and 70mL 
ddH20).  
 Protein levels were quantified using densitometry. Films were scanned in black and 
white for consistent analysis and images were analyzed using the gel analysis tools in the 
ImageJ software (Abràmoff et al., 2004).  
 
2.2.7 Analysis of Gene Expression 
2.2.7.1 Total RNA Isolation and Quantification 
 Total RNA was isolated using TRIzol Reagent (Life Technologies, Carlsbad, CA) 
following the manufacturer’s protocol with slight modifications. Human RNA was isolated 
using a kit per the manufacturer’s instructions (RNeasy Fibrous Tissue kit, Qiagen, USA). 
No more than 20mg of tissue or cells were homogenized in 1mL of TRIzol with a Dounce 
homogenizer. RNA was then extracted by adding 0.2mL of chloroform to the tube and 
shaken vigorously for 2-3 minutes at room temperature. Samples were centrifuged at 
12,000xg for 15 minutes at 4oC. The aqueous phase was carefully removed to a new tube. 
For RNA extraction of adult cardiomyocytes, RNase-free glycogen (5µg) was added to the 
tube to aid in RNA precipitation. 0.5mL of isopropanol was added to the new tubes and 
samples were placed at -20oC overnight to allow for RNA precipitation. The next day, 
samples were centrifuged for 10 minutes at 12,000xg. The pellet was washed one time with 
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1mL of 75% ethanol and allowed for air dry for 10 minutes. Pellets were resuspended in 
RNase-free H2O (20-50µl) and incubated at 60oC for 10 minutes.  
 Total RNA was quantified using a NanoDrop 1000 spectrophotometer (Thermo 
Scientific, Wilmington, DE). RNA quantity was determined using the Beer-Lambert Law, 
A=ECL (where A=absorbance, E=molar extinction coefficient [0.027 µg/mL/cm for single 
stranded RNA], C=concentration and L=light path) (Sambrook and Russell, 2001). The 
purity of the RNA was determined by the A260/280 ratio with a ratio of >1.8 accepted as pure 
RNA.   
RNA was reverse transcribed into cDNA in a separate reaction. 2ug of total RNA in a 
total of 12.5ul was added a nuclease-free tube followed by 7.5ul of reaction mix (0.5µl 
random hexamer primers [100pmol], 4µl 5x reaction buffer [Thermo Scientific], 2µl dNTPs 
[10mM], and 1µl reverse transcriptase [RevertAid, Thermo Scientific]). Samples were 
incubated for 10 minutes at 25oC followed by 60 minutes at 42oC. The reaction was 
terminated by heating at 70oC for 10 minutes. 
  
2.2.7.2 Quantitative Real Time Polymerase Chain Reaction (qPCR) 
Most primer and TaqMan probe sets were already available in the lab. Those not 
already available were designed using OligoArchitect (Sigma-Aldrich, St. Louis, MO). 
Quantification was performed by multiplexing with 6-FAM (reporter) / TAMRA (quencher) 
and JOE (reporter) / BHQ1 (quencher) dyes for the target and the GAPDH endogenous 
control, respectively. This dye pair was chosen because the large difference in emission 
maximum gives the lowest spectral overlap. ROX reference dye (Invitrogen, #12223-012) 
was used as a passive reference dye to control for non-related fluctuations in the 
fluorescence. The amplification of the more abundant GAPDH was limited by the primer 
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concentration. This serves to spare common reagents (dNTPs, Mg2+) for amplification of the 
target gene. The multiplex reaction mix was as follows: 
 
Multiplex PCR Mix   µl per Reaction (25µ)  Concentration in Reaction 
10X PCR Buffer    2.5   1X   
dNTPs 2.5mM     3   300nM  
MgCl2 50mM     2.5   5mM   
Primers-F/R target gene (20µM)       1.125 ea.             900nM  
Primers-F/R endogenous (20µM)  0.375 ea.  300nM 
50X Rox Reference Dye   0.5   1X   
Probes (10µM)      0.625 ea.  250nM   
Taq      0.5    
DEPC H20      4.25     
diluted cDNA (~1:20)    5 
 
To test for reaction efficiency, reactions were run in singleplex using a standard curve. The 
standard curve consisted of cDNA serially diluted ranging from 20pg-0.2fg. The reaction mix 
is as follows: 
 
PCR Mix  per well (25µl)  Concentration in Reaction  
10X PCR Buffer   2.5   1X   
dNTPs 2.5mM    2.5   250nM  
MgCl2 50mM    1.5   3mM   
Primers-F/R 20µM         0.75 ea.             600nM   
50X Rox Reference   0.5   1X   
Probe 10µM    0.25   100nM   
Taq     0.5    
DEPC H20     10.75     
diluted cDNA (~1:20)   5 
 
The standard curve is plotted on a linear scale as CT versus the concentration of the cDNA. 
The efficiency of the PCR can be determined from the slope of the standard curve using the 
formula: 
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Adequate efficiency was determined as having a slope between -3.58 and -3.10. The 
coefficient of correlation (R2) was required to be at least 0.98.  
 Gene expression was analyzed using the ABI Prism® Sequence Detection System. 
Transcript levels were evaluated using the comparative CT method (ΔΔCT method), 
normalized to GAPDH as an endogenous control, and expressed as a fold difference from 
control (Biosystems, 2008).  The comparative CT method eliminates the need for a standard 
curve by instead using the relative difference between the control and treated samples. 
Samples were run in triplicate and average ΔCT values for each sample for both the target 
gene and endogenous control was obtained through the software. All other calculations 
were performed in Microsoft® Excel. A simplified example: 
 
Sample 
GAPDH 
Avg. CT 
Target 
Avg. CT 
∆CT 
Target – GAPDH 
∆∆CT 
∆CT - (Avg. Control ∆CT) 
Fold Difference* 
2- ∆∆CT
 
Control 1 15.791 16.202 0.411 -0.285 1.218 
Control 2 16.667 17.329 0.662 -0.034 1.023 
Sample 1 16.374 15.869 -0.505 -1.201 2.298 
Sample 2 16.793 17.469 0.676 -0.02 1.013 
 
*For derivation of the formula 2- ∆∆CT, see Applied Biosystem’s User Bulletin #2: 
http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocument
s/cms_040980.pdf  
 
2.2.7.3. Restriction Enzyme Digest of PKM2 PCR Product 
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Analysis of pyruvate kinase alternative splicing was performed as previously 
described with minor changes (Clower et al., 2010). Alternative splicing of exon 9 and 10 of 
the PKM gene results in two identical length isoforms, PKM1 and PKM2 (Figure 2.2). Mouse 
and human primer sets were designed to amplify exons 8 through 11. cDNA products were 
digested with PstI, NcoI (New England Biolabs, Ipswich, MA), both or left undigested. 
Products were run on a 5% native polyacrylamide gel [12mL 5X TBE (TrisBase, Boric acid, 
EDTA), 10mL 30% acrylamide/Bis solution, 38mL DDH2O, 40ul TEMED, 400ul APS] at 30V 
in the cold room.  The gel was post-stained with ethidium bromide [0.5ug/mL] for 20 minutes 
followed by two 20 minute washes with ddH2O. Gels were imaged using a TD-1000R 
BiOVision dual-light transiluminator coupled to a camera. Images were analyzed using 
ImageJ.   
 
2.2.7.4 Gene Expression Microarray 
A gene expression microarray was performed by Vishnu Chintalgattu using a Mouse 
Genome 430 2.0 array gene chip purchased from Affymetrix (Santa Clara, CA). RNA from 
the hearts of mice treated with sunitinib or vehicle control for 3 or 7 days was used 
according to the manufacturer’s protocol.  
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Table 2.2. Primer and Probe Sequences for PCR and qPCR. 
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) Probe (5’-3’) 
m PKM  (exon 8-11) GTCTGGAGAAACAGCCAAGG CAACATCCATGGCCAAGTT N/A 
h PKM (exon 8-11)  AGAAACAGCCAAAGGGGACT CATTCATGGCAAAGTTCACC N/A 
m PKM1  GCTGTTTGAAGAGCTTGTGC TTATAAGAGGCCTCCACGCT [6fam]CCAGTCACTCCACAGACC[tam] 
m PKM2  CAGAGGCTGCCATCTACCAC TCCTCGAATAGCTGCAAGTG [6fam]GCCCGAGAGGCAGAGGCTGCC[tam] 
h PKM1 AGCTGTTTGAAGAACTTG CTCCGTCAGAACTATCAA [6fam]GGAGTGCGTCTTGTGTCAGAA[tam] 
h PKM2  GCCATCTACCACTTGCAA CTTGGTGAGGACGATTATG [6fam]CGGTGCATGCGTACTCCTTA[tam] 
m GAPDH GGTCTACATGTTCCAGTA CCCATTTGATGTTAGTGG [hex]ATTCAACGGCACAGTCAAGGC[bhq1] 
m 18S AGCTGAAACTTAAAGGAATTG CACGGAATCGAGAAAGAG [hex]TATCAATCTGTCAATCCTGTCCGTGT[bhq1] 
m hnRNPA1 AGGAGGTTCTAATTACATACA GCTGAGTTCACAAATCTG [6fam]CTGTCACTTCTCTGGCTCTCCTC[tam] 
m hnRNPA2 CTGTGAAGAAGCTGTTTG CAGGATCATGGTCATCAA [6fam]AAGGAAGATACTGAGGAACACCACC[tam] 
m PTB GGACCAAAGTTTAGCTTTC CCCCACAGGTATAAAATCA [6fam]ACTCTTCCACGCCTTCCACA[tam] 
m c-myc CGACTACGACTCCGTACAGC GTAGCGACCGCAAACATAGGA [6fam]CAGCAGAGCGAGCTGCAGCC[tam] 
m GLUT4 TTCTGACCAACTAAGGGCGG GTTCCTCCAGCACAGGACAC [6fam]GCTGCCTATAAACACTGGTT [tam] 
mr Hif1α GGAAGCGAAAAATGGAACATC TCACCTGGTTGCAGTAA [6fam]TTCCAATTCCTGCTGCTTGAAAAAGGG[tam] 
m PDK4 CTTTTCTGCGGCAAGAGCTG TTCACTAAGCGGTCAGGCAG [6fam]GGCCAATATCCTGAAGGAGA[tam] 
m Angptl4 GGGACTGCCAGGAACTCTTC GAAGTCCACAGAGCCGTTCA [6fam]GGGAGCGGCACAGTGGACTT[tam] 
m PHD3 AGGCAATGGTGGCTTGCTAT GACCCCTCCGTGTAACTTGG [6fam]CACCTGTATCTACTACCTGA[tam] 
mr GLUT1 CATCGTCGTTGGGATCCTTA GAGCAGTAGAGGCCACAAGTCT [6fam]AGGTGTTCGGCTTAGACT[tam] 
mr PDK1 GATCAGAAACCGGCACAATGA AGGATGCACCCCGAAGCT [6fam]CCATGGCCCAGGGTGTGACTGA[tam] 
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mr LDHa CGACTGCACCATGATCGTG TCCAGATTGCATCCACTTCC [6fam]AGGCACACTGGCGTCGCCATGCT[tam] 
mr αMHC GCAAAGGAGGCAAGAAGAAAGG TGAGGGTGGGTGGTCTTCAG [6fam]ACAGTGTCTGCTCTCCACCGGGAA[tam] 
mr βMHC  AGGGCGACCTCAACGAGAT CAGCAGACTCTGGAGGCTCTT [6fam]AGCTCAGCCATGCCAACCGTA[tam] 
mr c-fos GGTGCTGGATTGTATCTA TGGTCGTTTCTAATTGGA [6fam]CACGCTATTGCCAGGAACACAG[tam] 
mr ANF AGTGCGGTGTCCAACACAG CTTCATCGGTCTGCTCGCT [6fam]TCTGATGGATTTCAAGAA[tam] 
 
Table 2.2 Primer and Probe Sequences for PCR/qPCR. Sequences are listed in the 5’ to 3’ direction. Dyes used for each probe 
are denoted in brackets. Species is specified as: m, mouse; h, human’ r, rat.   
 Figure 2.2.  
Figure 2.2 Analysis of the PKM splicing by restriction enzyme digestion. 
displaying the cDNA products obtained using primers designed to amplify exon 8 through 
exon 11 of the PKM gene. (B) PKM isoform expression in the H9C2 rat cardiomyoblast cell 
line, isolated neonatal rat ventricular myocytes (NRVMs) or isolated adult mouse 
cardiomyocytes. The RT-PCR product was divided 
or digested with PstI (P), NcoI (N) or PstI plus NcoI (NP). (C) PKM isoform expression in 
U87 human glioblastoma cell line (as a positive control) or heart muscle samples from non
failing and failing human hearts.
 
into four aliquots and left 
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2.2.8 Enzyme Activity Assays  
 Spectrophotometry was used to indirectly measure the rate of the appearance of a 
product of an enzymatic reaction. A spectrophotometer consists of two instruments, a light 
source (spectrometer) and a photometer, for capturing the light. A sample is placed in a 
liquid cuvette between the two instruments such that a light beam passes through the 
sample where a portion is absorbed. When light of a single wavelength passes through the 
solution, there is a direct relationship (Beer’s Law) between the amount of light absorbed 
and the concentration of the reaction product 
(http://www.shimadzu.com/an/uv/support/fundamentals/structure.html): 
 Beer’s Law:   I = Io * 10-εcl 
Where I is the intensity of the light transmitted, ε is the reaction product’s absorption 
coefficient, c is the concentration of the reaction product and l is the length of the light path. 
Because the light path is constant, the equation can be rewritten to 
I / Io = 10-εcl = T 
T is the transmittance and there is a logarithmic relationship between the 
transmittance and the concentration of the reaction product such that 
-log T = log 1/T = εcl = Optical density (absorbance) 
Enzymes were extracted from whole tissue (~100mg) in 1mL of enzyme extraction 
buffer (50mM Tris-Base [pH 7.5], 100mM KCl, 5mM MgCl2, 1mM EDTA [pH 7.6], 1% Triton 
X-100 and L-glutathione [153mg/50mL]) using a Dounce homogenizer. Samples were 
centrifuged for 5 minutes at 4oC and the supernatant recovered in a new tube. All enzyme 
activity assay protocols were adopted from Bergmeyer’s Methods of Enzymatic Analysis 
(Bergmeyer, 2012). 
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2.2.8.1. Lactate Dehydrogenase Activity 
Lactate dehydrogenase enzyme activity was measured in a phosphate buffer (0.1M, 
pH 7.0) containing pyruvate (2.5mg/mL) and NADH (10mg/mL). Activity was measured as 
the change in absorbance due to the oxidation of NADH at 340nm and normalized to protein 
content.  
 
2.2.8.2. Pyruvate Kinase Activity 
 Pyruvate kinase activity was measured in a triethanolamine buffer (0.1M, pH 7.6) 
containing phosphoenolpyruvate, tri(cyclohexylammonium) salt (3.75mg/ml in 0.05M MgSO4  
/0.2M KCl buffer), ADP (30mg/mL, neutralized with KOH), NADH (10mg/mL) and LDH (from 
rabbit muscle, 32U/mL). Kinase activity was measured as the change in absorbance due to 
the oxidation of NADH at 340nm over the course of 12 minutes. Activity was normalized to 
protein concentration.   
 
2.3 Statistical Analysis 
 Except where noted, results are expressed as the mean ± the standard error of the 
mean (SEM). Analysis was performed using ABI Prism Graphpad software using a two-
tailed unpaired Student’s t test or one-way ANOVA with a Tukey post hoc test. A P value of 
> 0.05 was considered statistically significant. In general, *P < 0.05, **P < 0.01 and ***P < 
0.001. P values that differ from this convention are indicated within the graph.  
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Chapter 3           
MICROVASCULAR PERICYTES AS A PRIMARY TARGET 
OF SUNITINIB CARDIOTOXICITY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes 
1. A considerable amount of the work presented in this chapter was performed by Vishnu 
Chintalgattu, PhD (currently a Senior Scientist in Cardiovascular Research at Amgen, Inc., 
San Francisco, CA). The work is presented here with the permission of both Dr. Chintalgattu 
and Dr. Aarif Khakoo 
2.  Some figures are recreated from Chintalgattu, V., Rees, M.L., Culver, J.C., Goel, A., 
Jiffar, T., Zhang, J., Dunner, K., Pati, S., Bankson, J.A., and Pasqualini, R. (2013). Coronary 
Microvascular Pericytes Are the Cellular Target of Sunitinib Malate–Induced Cardiotoxicity. 
Science translational medicine 5, 187ra169-187ra169. (Chintalgattu et al., 2013), with 
permission from the American Association for the Advancement of Science (license number 
3466011035286).    
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3.1. Introduction 
This chapter demonstrates that a primary cause of sunitinib cardiotoxicity is loss of 
coronary microvascular pericytes, resulting in coronary microvascular and cardiac contractile 
dysfunction.  The data presented here show that loss of PDGFRβ signaling in the pericyte is 
a primary mechanism of sunitinib cardiotoxicity. Furthermore, I show that co-treatment with 
thalidomide preserves microvascular and contractile dysfunction without interfering with the 
anticancer efficacy of sunitinib. 
 
3.1.1. Regulation of myocardial blood flow.  
 Sunitinib is foremost an inhibitor of angiogenesis and, as will be demonstrated in this 
chapter, sunitinib treatment leads to a disruption of myocardial vascular stability and function 
(Chintalgattu et al., 2013). Thus, a basic review of the regulation of myocardial blood flow is 
warranted. For an in-depth review of the regulation of blood flow in the coronary 
microcirculation, I refer to (Muller et al., 1996; Rubio and Berne, 1975).  
Regulation of coronary blood flow is conceptually divided between regulation of the 
larger conduit vessels (>300µm in diameter), which confer little resistance to flow, and 
regulation of the smaller resistance vessels (<300µm in diameter) (Schelbert, 2010). Figure 
3.1.1 depicts the decline in blood flow velocity as a function of vessel cross-sectional area. 
The majority of coronary vascular resistance resides in the coronary arterioles less than 
150µm in diameter (Chilian et al., 1986). It is important to note that there is considerable 
heterogeneity even within the small resistance vasculature. Vascular reactivity can differ 
substantially from the large to small arterioles as well as between the subendocardium—
which is uniquely subject to the extravascular compressive forces of systole—and the 
subepicardium (Muller et al., 1996; Schelbert, 2010).  
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In the heart, the demand for oxygen is exactly matched by supply of oxygen through 
the coronaries. Unlike most other tissues, baseline extraction of oxygen is near maximal in 
the heart (Figure 3.1.2) (Gorlin, 1976). Accordingly, the primary mechanism to increase 
oxygen delivery to the myocardium is dilation of the small resistance vessels. At the same 
time, capillary pressure must remain constant to ensure efficient delivery of oxygen and 
nutrients (Muller et al., 1996). Angina pectoris—a painful tightening of the chest—occurs 
when myocardial oxygen demand exceeds coronary supply (Katz, 2010). It is important to 
note that oxygen delivery is also dependent on the hemoglobin content of the blood. For this 
reason, angina pectoris can result from severe anemia (Katz, 2010). Regulation of coronary 
vascular resistance is primarily controlled at local level, known as autoregulation, through 
myocardial production of metabolites, flow-mediated endothelial cell activation, and 
stimulation of the vascular smooth muscle (myogenic vasodilation) (Muller et al., 1996). The 
autonomic nervous system also controls vascular tone through activation of the alpha- and 
beta adrenergic receptors (Opie, 2004). The integration of signals leading to blood vessel 
dilation is summarized in Figure 3.1.3.  
Myocardial demand for increased oxygen is thought to be transmitted through 
accumulation of adenosine, a degradation product of AMP and ADP (Schelbert, 2010). 
Adenosine readily diffuses out of the cell where it binds to receptors on vascular smooth 
muscle cells, leading to decreased intracellular calcium and relaxation (Lilly and School, 
1998). Adenosine preferentially relaxes small arterioles compared to the larger vessels. 
Kantasuka and colleges demonstrated that rapid pacing of canine hearts led to dilation of 
both the large and small arterioles; however endogenous or exogenous supply of adenosine 
caused dilation in only the small arterioles (Kanatsuka et al., 1989). In addition to adenosine, 
other metabolic vasodilators include lactate, acetate and carbon dioxide (Katz, 2010).  
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Figure 3.1.1. 
 
 
Figure 3.1.1. Relation between vessel cross-sectional area and blood flow velocity. 
The largest resistance to blood flow in the heart is conferred by the smallest vessels in the 
heart. These vessels also account for the largest area in the heart. [Source: Rushmer, R.F. 
(1976). Cardiovascular Dynamics. (W.B. Saunders Company). (Rushmer, 1976)]. 
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Figure 3.1.2. 
 
 
Figure 3.1.2. Oxygen consumption by the heart and other organs. The heart consumes 
more oxygen than any other organ at rest. Skeletal muscle can increase oxygen extraction 
during exercise but cardiac muscle oxygen extraction remains constant. Cardiac oxygen 
consumption per minute (qO2) is equal to the difference between the arterial and venous 
percent oxygen multiplied by coronary flow. [Source: Gorlin, R. (1976). Coronary Artery 
Disease. (W.B. Saunders Company). (Gorlin, 1976)].  
60 
 
Figure 3.1.3. 
 
Figure 3.1.3. Integrated regulation of myocardial blood flow. Metabolic, myogenic and 
flow-dependent mechanisms act in a concerted manner to maintain proper oxygen delivery 
to the myocardium. [Source: Figure 5, Muller, J.M., Davis, M.J., and Chilian, W.M. (1996). 
Integrated Regulation of Pressure and Flow in the Coronary Microcirculation. Cardiovasc 
Res 32, 668-678. (Muller et al., 1996)]. Reused with permission from the journal. 
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In addition to of the effects of myocardial derived metabolites, microvascular tone is 
dependent on endothelial-mediated release of vasoactive compounds such as nitric oxide 
(NO), prostacyclin and endothelin-1. These factors are released from in endothelial cell in 
response to neural stimulation (i.e. acetylcholine), or shear-stress (also known as flow-
mediated vasodilation). NO is the primary mechanism through which endothelial cells induce 
relaxation. NO is synthesized by endothelial NO synthase (eNOS) where it diffuses to the 
adjacent smooth muscle and activates guanylyl cyclase, which converts guanosine 
triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). Increased intracellular 
cGMP leads to decreased Ca2+ levels and smooth muscle cell relaxation. Antagonism of 
eNOS with L-NG-nitroarginine methyl ester (L-NAME) in isolated porcine coronary 
microvessels produces constriction, indicating that there is tonic release of NO in the 
microvasculature (Kuo et al., 1991).  
Ultimately, vascular tone is dependent on the contraction and relaxation of vascular 
smooth muscle cells. This results from calcium-dependent phosphorylation and 
dephosphorylation of myosin by the myosin light chain kinases (MLCK) and myosin light 
chain phosphatases, respectively. The dynamics of the actin-myosin interaction and 
crossbridge cycling in mediating mural cell contraction or relaxation is of indirect relation to 
the work presented here and is discussed in Katz’ Physiology of the Heart or any other 
physiology textbook (Katz, 2010).  
While the microvasculature confers the largest resistance to flow, it is consists of 
relatively little vascular smooth muscle. Instead, the structure and function of the 
microvasculature is supported by pericytes, which are discussed in detail below (Armulik et 
al., 2005). 
3.1.2. Microvascular Pericytes 
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 Pericytes were first described by Carl Josef Eberth in 1871. However, their discovery 
is attributed to Charles-Marie Benjamin Rouget who in 1873 described “a population of cells 
closely associated with the endothelial cells of the microcirculation” (Armulik et al., 2005). 
Rouget cells were subsequently named pericytes nearly 50 years later by Karl Wilhelm 
Zimmermann, alluding to their perivascular location.  
Despite being the second most abundant cell type in the heart (Nees et al., 2012), 
evaluation of pericyte function in the heart has been limited until relatively recently. Pericytes 
have now been successfully isolated from a number or organs, including the heart (Nees et 
al., 2013). Due to their pluripotent nature pericytes are of particular interest in regenerative 
medicine, specifically post myocardial infarction (Gómez-Gaviro et al., 2012). 
 Most pericytes originate from the mesenchyme (Armulik et al., 2011). However, 
central nervous system and thymus pericytes are derived from the neural crest. Coronary 
pericytes arise from epicardial mesothelium (Armulik et al., 2011) where they undergo 
epithelial-to-mesenchymal transition, migrate into the interstitial space of the myocardium 
and fully differentiate. It is known that pericytes proliferate in vitro and in the CNS and may 
also differentiate from proliferating vascular smooth muscle cells (Nehls and Drenckhahn, 
1993). While the developmental origin of pericytes is well studied, much less is known about 
their origin and proliferation during angiogenesis in the adult.  
Pericytes are difficult to define as there is no single unequivocal marker that 
distinguishes them from other mesenchymal cells such as vascular smooth muscle cells and 
myofibroblasts. Nor is expression of any pericyte marker stable in its expression (discussed 
in more detail below). Therefore identification of pericytes relies on a combination of 
morphology, location, degree of vessel coverage and protein expression patterns. Key to 
their definition is that pericytes are embedded within the vascular basement membrane 
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which is continuous with the endothelial basement membrane (Armulik et al., 2005). Thus, 
definitive identification of pericyte requires detailed electron microscopy. Even then, 
pericytes are not always embedded in the basement membrane such as during active 
angiogenesis or certain disease states (Gomez et al., 2005).  
Pericytes consist of a single cell body with long processes that extend the abluminal 
length of multiple endothelial cells, attaching to the endothelial cells through peg-socket type 
contacts (Figure 3.1.4). Pericytes also contact endothelial cells though N-cadherin based 
adhesion plaques and possibly also through gap junctions (Armulik et al., 2005; Cuevas et 
al., 1984). Secondary processes extend perpendicular to the primary processes, circling 
around the endothelial tube and aiding with capillary contraction. The degree of pericyte 
coverage varies between organ types and exhibits a strong positive correlation with the 
barrier function of the tissue, ranging from 1:1 (pericyte: endothelial cell) in the blood brain 
barrier to as low as 1:10 in skeletal muscle (Diaz-Flores et al., 2009).  
Pericytes are ubiquitously expressed in all microvessels, principally in the capillaries 
but extending into both the precapillary arterioles and postcapillary venules (Nees et al., 
2013). The exact point at which pericyte coverage shifts to vSMC is controversial due to the 
fact that definitive distinction between the two cell types is challenging. Others have 
proposed that pericyte coverage extends into the largest coronary vessels, existing within 
the extracellular matrix between the endothelial tube and internal elastic membrane as well 
as supporting the vasa vasorum of the larger coronary arteries (Diaz-Flores et al., 2009). 
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Figure 3.1.4. 
 
  
 
Figure 3.1.4. Vascular pericyte coverage and pericyte anatomy.  
(A) A single layer of vascular smooth muscle cells (vSMCs) surround the larger arterioles. 
Beginning at the precapillary arteriole and then throughout the capillary, postcapillary venule 
and venule, the vessel is supported by pericytes. As opposed to vSMCs, pericytes display a 
prominent rounded cell body and long cytoplasmic processes. (B) Pericytes  and endothelial 
cells share a basement membrane and share many contacts [Source: Figure 1. Armulik, A., 
Genove, G., and Betsholtz, C. (2011). Pericytes: Developmental, Physiological, and 
Pathological Perspectives, Problems, and Promises. Dev Cell 21, 193-215. (Armulik et al., 
2011). Used with permission from Elsevier, permission number 3581440915913]. 
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Pericyte recruitment and stabilization of the endothelium is dependent on multiple 
signaling pathways, the complexity of which is demonstrated in Figure 3.1.5 and briefly 
described in the following sections.  
3.1.2.1 PDGF-B and PDGFRβ 
The platelet-derived growth factor (PDGF) family consists of three dimers comprised 
of two different disulfide linked polypeptide chains, PDGF-A and PDGF-B. The dimers most 
often exist as homodimers, PDGF-AA or PDGF-BB, however it was the heterodimer, PDGF-
AB, that was first discovered in activated platelets (Andrae et al., 2008). Recently, two 
additional PDGF factors, PDGF-C and PDGF-D have also been described (Bergsten et al., 
2001; Larochelle et al., 2001; Li et al., 2000). The PDGFs act in a paracrine manner, binding 
to heparin and heparin sulfate proteoglycans in the extracellular matrix through an essential 
C-terminal retention motif.  
PDGFs act via two structurally related tyrosine kinase receptors, platelet-derived 
growth factor receptor α and β (PDGFRα and PDGFRβ). PDGFRα can bind either PDGF-A 
or PDGF-B. However, PDGFRβ appears to bind only PDGF-B (Leveen et al., 1994). Binding 
induces receptor dimerization and activation of the downstream pathways Ras/MAPK, 
PI3K/Akt and PKC. This results in actin reorganization, cell growth, migration and inhibition 
of apoptosis (Andrae et al., 2008).  
During angiogenesis, PDGF-BB is produced by the endothelial tip cells and binds to 
PDGFRβ on the surface of developing pericytes (Gaengel et al., 2009). This process is 
dependent on retention of PDGF-BB in the extracellular matrix as deletion of this motif in 
mice (pdgfbret/ret) leads to pericyte detachment from the vessel wall and vascular 
malformations in the kidney and retina (Lindblom et al., 2003). Similarly, knockout of the N-
deacetylase/N-sulfotransferase (NDST)-1 enzyme, leading to a reduction of N-sulfated 
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heparin sulfate, also results in pericyte detachment (Abramsson et al., 2007). Deletion of 
PDGF-B or PDGFRβ leads to almost identical perinatal lethality due to vascular 
malformations resulting in widespread hemorrhage and edema (Armulik et al., 2011; Leveen 
et al., 1994; Soriano, 1994). Loss of PDGF-B or PDGFRβ in an in vivo model of brain 
angiogenesis resulted in endothelial cell hyperplasia, abnormal endothelial shape and 
increased vascular permeability. Embryos from PDGF-B deficient mice also display 
pronounced dilation of all chambers of the heart as well as significant enlargement of the 
thoracic aorta (Leveen et al., 1994).  
Only recently has the importance of PDGF-B/PDGFRβ signaling in maintaining 
pericyte coverage in the adult been explored. These investigations have focused mainly on 
tumor angiogenesis, diabetic retinopathy and neurobiology (Fernandez-Klett et al., 2010; 
Gee et al., 2003; Song et al., 2005; Winkler et al., 2011). Furthermore, my previous lab has 
reported that inducible cardiomyocyte-specific knockout of PDGFRβ in the adult mouse 
results in ventricular dilation and heart failure in response to pressure overload stress 
(Chintalgattu et al., 2010). This was correlated with impaired angiogenesis and 
microvascular dysfunction in the adult heart.  
3.1.2.2 Angiopoietin-1/Tie2 
Angiopoeitin-1/Tie2 paracrine signaling exists in a reciprocal orientation to PDGF-
B/PDGFRβ. That is, pericytes produce angiopoietin-1 which binds to the endothelial Tei2 
receptor, a receptor tyrosine kinase. Similar to PDGF-B/PDGFRβ, Angiopoeitin-1/Tie2 
signaling promotes vessel maturation and stability (Falcon et al., 2009; Gaengel et al., 2009) 
and reduced vessel leakiness (Thurston et al., 1999). Furthermore, angiopoeitin-1/Tie2 
signaling is essential for normal cardiac development (Armulik et al., 2011). Genetic deletion 
of either angiopoietin-1 or Tie2 leads death in utero due to cardiovascular abnormalities,  
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Figure 3.1.5. 
 
  
Figure 3.1.5. Signaling pathways mediating pericyte-endothelial cell interactions. The 
close interaction between endothelial cells and pericytes is regulated by a large number of 
pathways. However, the PDGF-B/PDGFRβ and Ang1/Tie2 interactions appear to be the 
most important. [Source: Figure 4. Armulik, A., Genove, G., and Betsholtz, C. (2011). 
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and 
Promises. Dev Cell 21, 193-215. (Armulik et al., 2011) Used with permission from Elsevier, 
permission number 3581440915913]. 
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characterized by detachment of the endocardium from the underlying myocardial wall and 
absence of trabeculae (Jones et al., 2001; Patan, 1998). Similarly, missense mutations in 
the human Tie2 receptor result in vascular malformations, resulting in multifocal bluish 
lesions on the skin and mucosa (Limaye et al., 2009; Vikkula et al., 1996). Multiple cell types 
produce angiopoietin-1, including other mesenchymal cells, cardiomyocytes, and 
hematopoietic cells; however the end result is much the same, promoting vascular stability 
and higher-order structure and reducing leakiness, reviewed by (Jones et al., 2001).  
3.1.2.3 Transforming growth factor beta 
Both endothelial and mural cells produce transforming growth factor beta (TGFβ). 
Signaling between the two is bidirectional and results in differentiation and maturation of the 
vessel. TGFβ induces a mural cell fate in undifferentiated mesenchymal cells, a process that 
is dependent on connexin-43 gap junction formation (Hirschi et al., 2003). TGFβ signals 
through two receptors in vascular cells activin receptor-like kinase (Alk)-1 and Alk-5, which 
have nearly opposing roles. Alk-5 activation inhibits migration and promotes mural cell 
differentiation, whereas Alk-1 phosphorylation induces a more proliferative state, reviewed in 
(Armulik et al., 2011). The two receptors are also regulated temporally, with Alk-1 
dominating early development and Alk-5 inducing differentiation in later phases (Schmierer 
and Hill, 2007). Deletion of downstream components of the TGFβ signaling pathway such as 
smad4 (Lan et al., 2007), smad5 (Chang et al., 1999) and endoglin (Li et al., 1999) result in 
embryonic lethality and vascular abnormalities.  
 
3.1.3. Strategies to increase pericyte coverage and vessel normalization. 
 Tumor vasculature is structurally and functionally abnormal. Vessels are dilated, 
tortuous, leaky and have absent or detached pericytes. This often results in interstitial 
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hypertension, acidosis and hypoxia (Jain, 2005). Paradoxically, depletion of tumor pericytes 
results in accelerated tumor growth and metastasis (Ramaswamy et al., 2003; Sennino et 
al., 2007). Recent work has demonstrated that increasing pericyte coverage prevents tumor 
growth. This process has been termed “vessel normalization”, because the vasculature 
reverts to a near-normal phenotype.   
3.1.3.1. Inhibition of VEGF-A 
 Treatment with bevacizumab, a monoclonal antibody directed against VEGF-A 
results in a pruning of poorly formed vessels, specifically ones lacking pericyte coverage 
(Winkler et al., 2004). Attempts to induce vessel normalization in cancer have focused 
primarily on inhibition of VEGF-A signaling. Interestingly, cardiotoxicity is not associated with 
agents that only inhibit VEGF-A signaling, such as bevacizumab (Khakoo et al., 2011). 
Vessel normalization also occurs with deletion of the pericyte marker, regulator of G-protein 
signaling 5 (RGS5), resulting in reduced leakiness and alleviation of hypoxia through an 
unknown mechanism (Hamzah et al., 2008). The only other strategy that has proved 
effective in normalizing tumor vasculature has been treatment with thalidomide. 
 3.1.3.2. Thalidomide 
 Thalidomide, a derivative of glutamic acid, was developed in the 1950s by the 
German company, Chemie Grünenthal, and used primarily to combat morning sickness in 
pregnant women. Though never approved by the FDA, thalidomide treatment led to severe 
birth defects (malformed limbs) in between 8,000 and 12,000 children born in Europe, 
Australia, Asia and South America (Bartlett et al., 2004). Thalidomide-induced teratogenicity 
is due to a direct inhibition of cereblon (CRBN) (Ito et al., 2010). CRBN forms an E3 ligase 
complex with damaged DNA binding protein 1 (DDB1) and Cul4A to target unidentified  
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Figure 3.1.6. 
 
 
Figure 3.1.5. CRBN is the primary target of thalidomide teratogenicity. Cereblon 
(CRBN) forms an E3 ligase complex with damaged DNA binding protein 1 (DDB1) and 
Cul4A to target unidentified substrates for degradation, leading to expression of fibroblast 
growth factor 8 (FGF8) and normal limb outgrowth. Thalidomide directly binds to CRBN and 
inhibits this process. [Source: Supplemental Figure 19 from Ito, T., Ando, H., Suzuki, T., 
Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., and Handa, H. (2010). Identification of a 
Primary Target of Thalidomide Teratogenicity. Science 327, 1345-1350. (Ito et al., 2010) 
Used with permission from the journal, license number: 3586070673111].  
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substrates for degradation, leading to expression of fibroblast growth factor 8 (FGF8) and 
normal limb outgrowth (Figure 3.1.6).   
The catalyst for the current use of thalidomide occurred in 1964 when Israeli 
physician Jacob Sheskin discovered that it could heal lesions in patients with erythema 
nodosum leprosum, a complication of leprosy (Sheskin, 1964). Nearly 30 years later, it was 
found that thalidomide had strong anti-inflammatory properties, primarily through inhibition of 
monocyte-derived tumor necrosis factor alpha (TNFα) (Sampaio et al., 1991). Within that 
same decade, thalidomide was found to be antiangiogenic (D'amato et al., 1994) and to co-
stimulate T-cells previously activated by T-cell receptor (Haslett et al., 1998). The TNFα-
mediated anti-inflammatory properties of thalidomide has led to its use in several other 
immune-system related complications such as Kaposi’s sarcoma (Little et al., 2000) and 
cachexia (Gordon et al., 2005). Thalidomide has also significantly improved survival in 
multiple myeloma, a B-cell derived malignancy that is associated with increased bone-
marrow microvascular density. Furthermore, its co-treatment with dexamethasone led to full 
remission in 10% of patients and partial remission in a quarter, leading to a clinical response 
rate of 32% (Singhal et al., 1999).  
Subsequently, two derivatives of thalidomide—lenalidomide and pomalidomide—
were developed which display 50,000 times more potency towards TNFα than thalidomide 
(Bartlett et al., 2004). These derivatives do not appear to cause teratogenicity yet retain the 
ability block angiogenesis. However as with thalidomide, the mechanism is still not well 
understood (Lu et al., 2009). In a mouse model of hereditary hemorrhagic telangiectasia, 
thalidomide increased pericyte coverage and induced vessel stabilization as well as 
increased PDGF-B in endothelial cells (Lebrin et al., 2010). This chapter will demonstrate 
that co-treatment with thalidomide can protect from sunitinib-induced pericyte loss and 
preserve contractile function in mice. 
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3.2 Results 
3.2.1 Sunitinib induces cardiomyocyte hypertrophy. 
 Mice were treated with sunitinib for 21 days, a schedule that mimics the three weeks 
on, one week off, clinical treatment schedule (see methods).  Sunitinib treatment did not 
result in increased heart weight to body weight ratios, which is normally indicative of cardiac 
hypertrophy (Figure 3.2.1A). Nor was there evidence of pulmonary edema, as indicated by 
normal lung weight to body weight ratios (Figure 3.2.1B). However, the increased 
cardiomyocyte cross-sectional area (Figure 3.2.1C) suggests that there is cellular 
hypertrophy despite no change in overall heart size.  
 Because sunitinib causes severe hypertension, mean-arterial pressure (MAP) was 
measured over the course of treatment. Mice do not readily develop hypertension. Therefore 
it was not much of a surprise that there was no increase in MAP (Figure 3.2.1D). This 
indicated that sunitinib-induced cardiotoxicity may be the result of a direct cellular effect, and 
not secondary to hemodynamic stress.  
 
3.2.2 Sunitinib-induced cardiac contractile dysfunction is associated with 
coronary microvascular dysfunction.  
 Measurement of left-ventricular ejection fraction by cardiac MRI revealed a 
progressive decline over the course of 21 days (Figure 3.2.2A). This was associated with 
decreased cardiac contractility in response to the inotropic agent dobutamine (Figure 
3.2.2B), measured by the maximum developed pressure in the left ventricle over time 
(dP/dtmax).  
  
 Figure 3.2.1. 
Figure 3.2.1. Sunitinib increases cardiomyocyte cross
evidence of increased heart size. 
body weight ratio. (C) Lectin
cardiomyocyte cross-sectional area quantified to the right.  
the course of the 21 day treatment.  
 
-sectional area despite no 
(A) Heart weight to body weight ratio. (B) 
-TRITC staining to demark cardiomyocyte cell boarders and 
(D) Mean arterial pressure over 
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Lung weight to 
 Figure 3.2.2. 
Figure 3.2.2. Sunitinib treatment leads to contractile and microvascular dysfunction. 
(A) Cardiac ejection fraction as assessed by cardiac MRI. 
over time (dP/dtmax) in the left ventricle in response to increasing concentration of 
dobutamine. (C) Representative ultrasound tracings of stimulated and basal coronary flow in 
the left-anterior descending coronary artery after 14 days of sunitinib treatment. Average 
CFR (dilated:basal) over the 21 day treatment protocol. *P < 0.05.
(B) Maximum developed pressure 
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Coronary flow reserve (CFR), the change in blood flow velocity in the coronary artery 
in response to a hyperemic stimulus, is clinically relevant measure that has been eloquently 
adapted for the mouse heart (Hartley, Ultrasound in Medicine and Biology, 2008). Baseline 
coronary flow is often elevated under load-induced cardiac hypertrophy in order to support 
increased cardiac work (Hartley et al., 2011; Hartley et al., 2008). Consequentially, the 
absolute rise to maximal coronary blood flow velocity, the coronary flow reserve, in blunted 
in diseased states. Baseline coronary flow (1% isoflurane) was elevated in the sunitinib-
treated and blunted upon stimulation (elevation of isoflurane levels to 2.5%), resulting in a 
significantly decreased CFR in the sunitinib treated mice (Figure 3.2.2C). Collectively, these 
results indicate that sunitinib-induced cardiotoxicity is associated with microvascular 
dysfunction.  
 
3.2.3. Sunitinib treatment results in reduced vascular reactivity. 
 Acetylcholine stimulation of the endothelium leads to activation of endothelial nitric 
oxide synthase (eNOS) and consequent endothelium-dependent vascular relaxation and 
increase in blood flow. Similar to isoflurane, acetylcholine infusion revealed that sunitinib 
treatment leads to decreased CFR in vivo (Figure 3.2.3A). The same result was obtained 
when acetylcholine-mediated increases in total coronary flow were measured using the ex 
vivo Langendorff perfused heart preparation (Figure 3.2.3B). Ex vivo total coronary flow was 
also decreased upon stimulation with the direct nitric oxide (NO) donor, sodium nitroprusside 
(Figure 3.2.3C). As a direct donor of NO, sodium nitroprusside bypasses the endothelium to 
directly induce vasorelaxation.  Therefore, sodium nitroprusside is useful to determine if the 
defect in vascular function resides in the ability of the mural cells to respond to NO. Given 
the fact  
 Figure 3.2.3. 
Figure 3.2.3. Sunitinib is associated with decreased vascular reactivity. (A) 
Acetylcholine-stimulated coronary flow reserve in mice treated with sunitinib
days measured in vivo. (B)
treated with sunitinib for 14 days. 
concentration of sodium nitroprusside or adenosine meas
perfused hearts from mice treated with sunitinib or vehicle. 
 Acetylcholine-stimulated ex vivo total coronary flow in mice 
(C) and (D) Total coronary flow in response to increasing 
ured in ex vivo
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that ex vivo total coronary flow was also decreased in response to adenosine (endothelium-
dependent) (Figure 3.2.3D), it appeared that sunitinib-induced microvascular dysfunction 
might be due to vSMC or pericyte dysfunction. 
 In order to determine if sunitinib treatment also leads to macrovascular dysfunction, 
vascular reactivity was assessed in isolated thoracic aortas with the help of Dr. Nathan 
Bryan at The University of Texas’ Institute of Molecular Medicine. Isolated thoracic aortas 
from mice treated with sunitinib or vehicle were exposed to phenylephrine or acetylcholine to 
measure vascular constriction and relaxation, respectively (Figure 3.2.4A and Figure 
3.2.4B). Sunitinib treatment had no effect on vasoconstriction or vasorelaxation of the large 
vessels. However, there was a significant decrease in cardiac nitrite concentrations, a 
byproduct of NO breakdown (Figure 3.2.4C). This indicated that sunitinib somehow alters 
the ability of the cardiac vasculature to metabolize NO. Interestingly, there was no difference 
in skeletal muscle nitrite levels, suggesting that sunitinib-induced vascular dysfunction may 
be specific to the heart.  
 
3.2.4. Sunitinib treatment leads to loss of microvascular pericytes and microvascular 
abnormalities.  
 As described above, the largest resistance to flow in the heart is conferred by the 
cardiac microvasculature. Supporting these small vessels are pericytes which, similar to 
smooth muscle cells on larger vessels, provide structural and functional support. Scanning 
electron microscopy revealed a loss of microvascular pericytes in sunitinib-treated hearts 
(Figure 3.2.5A). This was confirmed by immunofluorescent microscopy of cardiac sections 
stained for the proteoglycan neural/glial 2 (NG2), an established marker for pericytes  
 Figure 3.2.4. 
Figure 3.2.4. Sunitinib does not affect large
contraction or relaxation of isolated thoracic aortas
vehicle stimulated with phenylephrine (PE) or acetylcholine (Ach). 
concentration in cardiac and skeletal muscle tissue, respectively. *P < 0.05.
-vessel reactivity. (A) and (B) 
 from mice treated with sunitinib or 
(C) and (D) 
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(Ozerdem et al., 2001). Decreased NG2 expression was also observed by western blot 
(Figure 3.2.5C).  
 Next, the functional consequence of pericyte loss in the heart was determined. 
Pericyte loss has been linked to increased vascular permeability in both the blood-brain 
barrier and tumors (Lindahl et al., 1997; Mccarty et al., 2007). Perfusion of isolated mouse 
hearts with fluorescently labeled cadaverine, which in a healthy vasculature would remain 
within the vessel, suggested that sunitinib treatment leads to increased vascular 
permeability in the heart (Figure 3.2.6A). Absence of pericytes is also associated with 
immature, poorly formed vessels which can be assessed by measuring vascular tortuosity 
(Gaengel et al., 2009; Higuchi et al., 2000). Vascular tortuosity was significantly increased in 
hearts from sunitinib-treated mice, as measured by a blinded third party (Dr. Jim Culver, as 
a graduate student in the lab of Dr. Mary Dickinson at Baylor College of Medicine).  
Together these data suggest that pericyte loss leads to a leaky, poorly formed vasculature. 
They also indicate that the cardiac vasculature is dynamic, continuously remodeling in 
response to stress.   
 
3.2.5. Cardiac pericyte loss is also observed with the structurally distinct PDGFRβ 
inhibitor, CP-673,451.  
 Noting that PDGFRβ signaling is essential for pericyte survival, it appeared that 
sunitinib-induced pericyte loss might be due to inhibition of PDGFRβ. CP-673,451 is a 
potent and specific PDGFRβ inhibitor that is structurally distinct from sunitinib (Figure 
3.2.7A) (Roberts et al., 2005). Similar to sunitinib, treatment with CP-673,451 did not lead to 
increased heart weight to body weight or lung weight to body weight ratios (Figure 3.2.7B). 
However, a similar decline in left-ventricular ejection fraction was observed (Figure 4.2.7C) 
 Figure 3.2.5. 
Figure 3.2.5. Sunitinib treatment induces loss of microvascular pericytes. (A) 
Representative scanning electron microscopy images of the cardiac microvasculature. 
Vessels and pericytes are psuedocolored red and green respectively. 
from cardiac sections showing staining for the endothelial cell marker CD31 (red), pericyte 
marker NG2 (green) or nuclear staining (DAPI, blue) and merged images (bottom left). 
Pericyte coverage quantified to the right as the relative intensity 
protein expression in mice treated with sunitinib or vehicle. Right, densitometric 
quantification. 
(B) Confo
of NG2:CD31. 
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cal images 
(C) NG2 
 Figure 3.2.6. 
Figure 3.2.6. Pericyte loss leads to microvascular abnormalities. (A) 
confocal images from mice treated w
conjugated to Alexa Fluor-555
Computer-based reconstruction of the cardiac vasculature derived from the apex hearts 
perfused with 70-kD tetramethylrh
vascular tortuosity. ***P < .01. 
 
ith sunitinib and perfused with 0.9 
 demonstrating increased microvascular permeability. 
odamine-labeled dextran and (below) quantification of 
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 Figure 3.2.7. 
Figure 3.2.7. Coronary microvascular dysfunction and pericyte loss are recapitulated 
with the structurally distinct PDGFR
sunitinib and CP-673451. (B)
ratios for mice treated with CP
treatment as measured by cardiac MRI. 
673451 treatment. (E) Representative confocal micrographs showing staining for the 
vascular marker CD31 (red) or the pericyte marker NG2 (green) and merged images. 
 
β inhibitor, CP-673451. (A) Chemical structures of 
 Heart weight to body weight and lung weight to body weight 
-673451. (C) Cardiac ejection fraction at 7 and 14 days of 
(D) Coronary flow reserve at day 7 and 14 of CP
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 and coronary flow reserve (Figure 3.2.7D). Most strikingly, CP-673,451 treatment resulted 
in a similar loss of cardiac microvascular pericytes (Figure 3.2.7E). These data suggest that 
loss of PDGFRβ signaling underlies the development of contractile and microvascular 
toxicity due to sunitinib. 
 
3.2.6. Pericyte loss is not a general feature of cardiotoxicity. 
 As described in Chapter 1, doxorubicin is a general DNA intercalating agent that 
causes cardiac injury through the generation of reactive oxygen species. Both low dose 
(5mg/kg/wk.) and high dose (10mg/kg/wk.) doxorubicin treatment led to decline in left-
ventricular ejection fraction (Figure 3.2.8A) and coronary flow reserve (Figure 3.2.8B). 
However, there was no observable loss of the pericyte marker NG2 by either western blot 
(Figure 3.2.8C) or immunofluorescence (Figure 3.2.8D). Therefore pericyte loss appears to 
be a specific feature of sunitinib cardiotoxicity and not a general feature of cardiac injury by 
chemotherapeutic agents. 
3.2.7. Co-treatment with thalidomide ameliorates sunitinib-induced contractile 
dysfunction and pericyte loss.  
To test whether sunitinib was directly toxic to pericytes in vitro, the viability of human 
placental pericytes treated with sunitinib was determined using an MTT colorimetric assay 
(see methods).  Cell viability was inversely correlated with the concentration of sunitinib 
(Figure 3.2.9A). As described above, thalidomide is known to increase vascular pericyte 
coverage. Co-treatment of isolated pericytes with sunitinib and thalidomide significantly 
increased cell viability, though not to control levels (Figure 3.2.9B). Neither sunitinib alone  
  
 Figure 3.2.8. 
Figure 3.2.8. Doxorubicin treatment does not cause pericyte loss. (A) 
fraction in mice treated with doxorubicin or vehicle, measured by cardiac MRI. 
flow reserve at day 1, 7 and 14 of treatment. 
lysates of mice treated with doxorubicin or vehicle. 
endothelial marker CD31 (red), pericyte marker NG2 (green), nuclei (DAPI, blue) and 
merged images.  
(C) NG2 protein expression from cardiac 
(D) Confocal micrographs stained 
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Figure 3.2.9. Sunitinib-induced pericyte death is rescued by thalidomide 
Pericyte viability measured by <
concentrations of sunitinib. (B) 
or plus thalidomide. (C) Neither sunitinib alone nor co
fibroblast or endothelial cell viability.  
TT assay after 24 hour treatment with increasing 
Pericyte viability after 24 hour treatment with sunitinib alone 
-treatment with thalidomide affects 
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nor co-treatment with thalidomide had any effect on fibroblast or endothelial cell viability 
(Figure 3.2.9C). This suggests that sunitinib-induced cardiotoxicity may be directly related to 
its effects on pericytes and that pericytes are specifically protected by thalidomide. 
Therefore, if thalidomide could restore pericyte coverage in the heart, sunitinib 
induced cardiotoxicity might be prevented. Mice were treated with sunitinib alone or sunitinib 
plus thalidomide for 14 days followed by 14 days of recovery. Thalidomide protected from 
both sunitinib-induced reductions in both contractile (Figure 3.2.10A) and microvascular 
(Figure 3.2.10B) dysfunction during the treatment phase and this protection extended into 
the recovery period. Lastly, confocal microscopy revealed that thalidomide co-treatment 
preserved pericyte coverage of coronary microvessels (Figure 3.2.10C). These findings 
demonstrate that sunitinib-induced pericyte depletion may be directly responsible for 
sunitinib-induced cardiac dysfunction. 
 
3.2.8. Thalidomide does not alter the anti-tumor efficacy of sunitinib. 
 To determine whether thalidomide may represent a novel strategy for 
cardioprotection during sunitinib treatment, the ability of sunitinib to halt tumor growth was 
evaluated in the presence of thalidomide. As a single treatment, thalidomide only mildly 
slowed tumor growth compared to sunitinib in a human renal cell carcinoma xenograft model 
(Figure 3.2.11A). However more importantly, the rate of tumor growth with co-administration 
of thalidomide and sunitinib was no different than sunitinib alone. As observed in non-tumor 
bearing mice, co-treatment with thalidomide protected from sunitinib-induced contractile 
dysfunction (Figure 3.2.11B) and decrease in coronary flow reserve (Figure 3.2.11C). 
Collectively, this data demonstrates that co-treatment with thalidomide may be a viable 
strategy for cardioprotection in patients receiving sunitinib.  
 Figure 3.2.10. 
Figure 3.2.10. Co-treatment with thalidomide prevents sunitinib
cardiovascular dysfunction and pericyte loss. (A) 
mice treated with sunitinib alone (control) or sunitinib plus thalidomide (thalidomide) for 14 
days followed by a 14 day recovery period. 
sunitinib alone or sunitinib plus thalidomide. Data is shown as the flow reserve index, or the 
ratio of mice treated with sunitinib alone to mice treated with sunitinib plus vehicle
Confocal micrographs stained for the endothelial marker CD31 (red), pericyte marker NG2 
(green), nuclei (DAPI, blue) and merged images.  *P < 0.05. 
Left-ventricular ejection fraction in 
(B) Coronary flow reserve in mice treated with 
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 Figure 3.2.11. 
Figure 3.2.11. Co-treatment with thalidomide does not alter the anti
of sunitinib. (A) Average tumor volume over time in untreated mice or mice treated with 
sunitinib alone, thalidomide alone or sunitinib plus thalidomide. 
ejection fraction and coronary flow reserve in tumor
treatment. *P < 0.05.  
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4. Discussion 
The data presented here indicate that the primary cellular target of sunitinib is the 
pericytes surrounding the coronary microvasculature. Furthermore, pericyte loss leads to 
vascular abnormalities and cardiac dysfunction in the adult heart. It is known that pericyte 
loss leads to abnormal cardiac development and death during development (Bjarnegard et 
al., 2004; Jeansson et al., 2011). The data I presented here suggest that pericyte survival is 
similarly essential in the adult heart.  
Sunitinib-induced cardiac dysfunction is mostly reversible with drug withdrawal 
(Uraizee et al., 2011); both cardiac and microvascular dysfunction slowly return to normal, 
suggesting that pericyte coverage also increases (Figure 3.2.10). It remains to be 
determined whether sunitinib treatment induces pericyte apoptosis in vivo, similar to pericyte 
loss in diabetic retinopathy (Geraldes et al., 2009). Or, whether the pericytes dedifferentiate 
and migrate away from the endothelium as occurs during cerebral ischemia (Thomas, 1999). 
My in vitro experiments (Figure 3.2.9) reveal a direct toxic effect of sunitinib on pericytes, 
suggesting that sunitinib treatment leads to pericyte cell death in the heart. Thus, the 
restoration of pericyte coverage may be the result of the transdifferentiation of 
myofibroblasts, smooth muscle cells or even endothelial cells in the heart (Deruiter et al., 
1997; Nehls and Drenckhahn, 1993). Future studies may take advantage of cellular fate 
mapping tools, such as endothelial cell-specific expression of a myristoylated mCherry 
fluorescent protein (Poche et al., 2009), to determine the source of pericytes in the 
recovering sunitinib-treated heart. 
 The mechanism by which thalidomide protects from sunitinib-induced pericyte death 
remains unknown. Loss of microvascular pericytes in rat models of both Type I 
(streptozotocin-induced) or Type II (Zucker Diabetic Fatty rat) diabetes is associated with 
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high levels of TNFα (Behl et al., 2008). TNFα was also associated with pericyte 
dedifferentiation and proliferation in an experimental model of autoimmune 
encephalomyelitis (Tigges et al., 2013). Furthermore, pharmacological blockade of TNFα is 
sufficient to prevent pericyte cell death both in vitro and in vivo (Behl et al., 2008; Joussen et 
al., 2009; Tigges et al., 2013). Blockade of TNFα is the primary mechanism by which 
thalidomide improves autoimmune diseases and slows growth in multiple myeloma. 
Therefore it’s possible that protection of coronary microvascular pericyte from sunitinib-
induced cell death may be due to inhibition of TNFα. It would be interesting to determine if 
specific inhibition of TNFα could protect from sunitinib-induced cardiotoxicity. Although the 
combination of sunitinib and thalidomide did not slow tumor growth beyond sunitinib 
treatment alone (Figure 3.2.11), it is possible that more potent inhibition of TNFα—such as 
with lenalidomide or pomalidomide—in combination with sunitinib would be beneficial. In 
fact, several clinical trials evaluating lenalidomide as a single treatment for metastatic renal 
cell carcinoma have demonstrated positive results (Amato et al., 2008; Choueiri et al., 2006; 
Pal et al., 2012).  Additional clinical studies will be necessary to determine whether sunitinib-
induced coronary microvascular dysfunction and pericyte loss also occur in humans, and 
whether thalidomide represents a rational cardioprotection strategy for patients at high risk 
for cardiotoxicity due to sunitinib. 
Pericyte loss is not a general feature of cardiac injury (Figure 3.2.8). Nonetheless, 
pericyte loss occurs during cerebral ischemia and in the early phases of diabetic retinopathy 
(Geraldes et al., 2009; Thomas, 1999). Therefore, it would be interesting to determine 
whether pericyte loss occurs in other forms of heart failure such as ischemic cardiomyopathy 
or diabetic cardiomyopathy. Along that same line, the exact mechanism by which pericyte 
loss leads to cardiac dysfunction remains to be fully explored. To this end, my previous lab 
performed gene expression microarrays on mice treated with sunitinib or vehicle for 3 or 7 
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days (Figure 3.2.12). Of 51 genes upregulated by at least 15%, 14 genes are known to be 
regulated by hypoxia inducible factor 1 alpha (Hif1α). Of these 14 genes, PHD3, BNIP3, c-
myc, Angptl4, and EDN1 are specifically upregulated in the hypoxic heart. It is possible that 
sunitinib-induced microvascular dysfunction leads to myocardial hypoxia, inducing a state 
similar to the hibernating myocardium (Ammirati et al., 2011; Kloner et al., 1989). 
Hibernating myocardium is defined as dysfunctional but still viable tissue and is discussed 
most often in the setting of left ventricular systolic dysfunction due to coronary artery 
disease. My data presented in the next chapter will suggest a possible connection between 
pericyte loss, hypoxia and dysfunction.  
Lastly, pericyte loss may not be the only mechanism by which sunitinib could cause 
cardiac dysfunction. As discussed in Chapter 1, sunitinib has also been shown to directly 
inhibit adenosine monophosphate activated kinase (AMPK) (Kerkela et al., 2009; Laderoute 
et al., 2010). Sunitinib-induced changes in cardiac metabolism, specifically increased 
glucose metabolism, are the subject of the next chapter.  
  
 Figure 3.2.12. 
Figure 3.2.12. Microarray analysis of hearts from mice treated with sunitinib or vehicle 
for 3 or 7 days. (A) Fold change in expression of
identified by the Affymetrix microarray. 
expression in the hearts of mice treated with sunitinib for 3 or 7 days. *P<0.05. 
 
 
 selected genes associated with hypoxia
(B) qPCR confirmation of increased PHD3 
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Chapter 4           
Altered Glucose Metabolism and a PKM2 Signature in the 
Failing Heart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Several figures presented here are published in (Rees et al., 2015) Used with 
permission from Elsevier, license number: 500977596.
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4.1 Introduction 
 
4.1.1 Sunitinib lowers blood glucose levels in patients. 
In addition to inducing cardiovascular dysfunction in a subset of patients, sunitinib 
dramatically lowers blood glucose levels in both diabetic and non-diabetic patients. 
Beginning as far back as 2004, a sprinkling of case reports have described a normalization 
of blood glucose levels in diabetic patients receiving sunitinib or the related receptor tyrosine 
kinase inhibitors imatinib, sorafenib and dasatinib (Billemont et al., 2008; Breccia et al., 
2005; Breccia et al., 2004; Louvet et al., 2008; Mokhtari and Welsh, 2010; Templeton et al., 
2008; Tsapas et al., 2008; Veneri et al., 2005). Agostino et al performed a retrospective 
study of blood glucose levels in both diabetic (17) and non-diabetic (61) patients treated 
with: imatinib (39), sunitinib (30), sorafenib (23) or dasatinib (8) (Agostino et al., 2011). The 
authors found significant decreases in blood glucose levels ranging from 53 mg/dL with 
dasatinib to 9 mg/dL with imatinib. Importantly, 47% (8/17) of the diabetic patients 
discontinued their medications, including some patients on insulin treatment.  
 Common to all these RTKIs is inhibition of PDGFRβ, Accordingly, the proposed 
mechanism for this phenomenon has thought to be the preservation of pancreatic beta cells 
through inhibition of PDGFRβ. In the most prominent paper promoting this hypothesis, the 
authors found that only drugs whose targets include the PDGFRβ (imatinib, sunitinib and a 
PDGFRβ-Ig) could both reverse and prevent the development of diabetes in the NOD 
mouse model of type I diabetes (Louvet et al., 2008). This was compared to specific 
inhibition of c-kit with PLX647, a monoclonal antibody that has also been proposed to 
mediate glycemic control (Mokhtari and Welsh, 2010). Several other investigators 
demonstrated preservation of pancreatic beta cells both in streptozotocin-treated rats and in 
the db/db mouse (Hagerkvist et al., 2008; Han et al., 2009). However this class of drugs, 
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specifically ones that target PDGFRβ, lower blood glucose levels in patients with type 2 
diabetes as well, suggesting an alternative mechanism of glycemic control besides 
preservation of pancreatic beta cells, namely increased insulin action in the peripheral 
tissues. This concept is supported by the observation that imatinib increased insulin 
sensitivity and glucose disposal rates in rats fed a high fat diet (Hagerkvist et al., 2008). 
Based on electron microscopy images demonstrating apparent mitochondrial 
structural abnormalities in the heart, Force et al proposed that cardiotoxicity due to imatinib 
and sunitinib may be due to mitochondrial defects (Force et al., 2007). Following this 
observation, a group at the pharmaceutical company Pfizer measured mitochondrial function 
in isolated rat mitochondria and H9C2 cells treated with imatinib, sunitinib, sorafenib and 
dasatinib (Will et al., 2008). Of the four kinase inhibitors tested, only sorafenib significantly 
affected isolated mitochondrial function and resulted in decreased ATP content in H9C2 
cells. This indicated that mitochondrial dysfunction is most likely not the cause of sunitinib 
cardiotoxicity and confirmed the sentiment that the membrane whorls observed on 
transmission electron micrographs were most likely a freezing artifact (Dr. Michael Ewer, MD 
Anderson Cancer Center, personal communication).  
 
4.1.2 Increased glucose metabolism and induction of the fetal gene program in 
the failing heart.  
Mounting evidence from our lab and others indicates that glucose uptake in excess 
of the heart’s capacity to oxidize glucose contributes to cardiovascular dysfunction. For 
instance, the ACCORD trial found that intensive glucose lowering therapies (targeted 
HbA1C levels below 6%) actually increase the incidence of death from cardiovascular 
disease in patients with type 2 diabetes. Given this high association between intensive 
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glucose lowering and cardiovascular dysfunction, I asked whether sunitinib similarly drives 
glucose uptake in excess of the heart’s oxidative capacity.  
A hallmark of the fetal heart is the use of carbohydrate substrates as the primary 
source of energy (Rajabi et al., 2007). The greater efficiency of carbohydrate substrates per 
mole of oxygen allows the fetal heart to withstand its low oxygen environment, rapidly 
changing hemodynamic load and demand for growth (Rajabi et al., 2007). Shortly after birth, 
as the maternal supply of nutrients is lost, the heart is exposed to a period of starvation 
where it rapidly depletes its glycogen stores and promptly switches to the oxidation of fatty 
acids. This process appears to require the induction of autophagy as deletion of the 
autophagasome elongation factor, ATG5, results in rapid post-natal lethality (Kuma et al., 
2004). Though displaying a preference for fatty acids, the adult heart is an omnivore, 
capable of utilizing a wide range of additional carbon sources, such as lactate and ketone 
bodies, in response to metabolic milieu and hemodynamic load (Taegtmeyer, 1994).   
 The failing heart returns to predominant glucose utilization for energy provision. This 
is achieved, in part, through induction of the fetal gene program. The primary argument for 
this effect relates to the higher efficiency of glucose oxidation compared to the oxidation of 
fatty acids. The most convincing evidence for this comes from a study in the isolated 
working rat heart subjected to an abrupt increase in cardiac work (Goodwin et al., 1998) and 
a study by Korvald et al (Korvald et al., 2000). In this study, myocardial oxygen consumption 
and cardiac performance were measured in vivo using anesthetized pigs. For the same 
amount of cardiac work, oxygen consumption was 48% higher when pigs were infused with 
intralipid-heparin (IH) compared to infusion of glucose, insulin and potassium (GIK). 
Alternatively stated, for the same amount of oxygen consumed, glucose supports 
significantly more cardiac work. For this reason, activation of the fetal gene program is 
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thought to be mostly adaptive, provided glucose uptake and oxidation are matched (Rajabi 
et al., 2007).  
Prominent features of the fetal gene program include myosin heavy chain (MHC) 
isoform switching from MHCα to MHCβ, expression of atrial naturietic factor (ANF) and 
activation of the transcription factors c-myc and c-fos (Rajabi et al., 2007). The switch to 
glucose oxidation results from primarily from the downregulation of adult genes such as 
GLUT4, pyruvate dehydrogenase kinase 2 (PDK2), muscle carnitine palmitoyl transferase 1 
(mCPT-1) and medium-chain acyl-CoA decarboxylase (MCAD), (Barger and Kelly, 1999; 
Razeghi et al., 2001). In the course of work on my dissertation I have shown that induction 
of another fetal gene, the M2 isoform of pyruvate kinase (PKM2), may provide a link 
between activation of the fetal gene program and upregulation of glycolysis. 
 
4.2 Results 
4.2.1. Sunitinib treatment results in increased insulin sensitivity. 
 In order to test whether sunitinib affects blood glucose levels regardless of diabetic 
status, I tested insulin sensitivity in non-diabetic C57BL/6J mice. Sunitinib treated mice had 
decreased serum glucose levels (Figure 4.2.1A) despite significantly decreased circulating 
insulin levels (Figure 4.2.1B). This suggested to me that sunitinib increases insulin 
sensitivity as both groups consumed the approximately same number of calories per mouse 
per day (Figure 4.2.1C). Significantly increased insulin sensitivity was confirmed by an 
insulin tolerance test (Figure 4.2.1D) as well as by the slightly enhanced glucose clearance 
observed in an oral glucose tolerance test (Figure 4.2.1E).  
 Based on these findings, hyperinsulinemic euglycemic clamp studies were performed 
in the Mouse Metabolism Core at Baylor College of Medicine. The hyperinsulinemic 
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euglycemic clamp is considered the gold standard by which to characterize insulin sensitivity 
(Defronzo et al., 1979). Measurement of tissue-specific glucose uptake can be achieved 
using [U-14C]-2-deoxyglucose (2DG), or the related tracer, 2-deoxy-2-[18F]fluoro-D-glucose 
(FDG) (Figure 4.2.2A).  
2DG and FDG are readily taken up by the cell and phosphorylated but not further 
metabolized, permitting an estimation of tissue glucose uptake (Nguyen et al., 1990). It is 
important to note, however, that glucose uptake is underestimated when 2DG is used, 
making assessment of myocardial glucose uptake with 2DG is qualitative rather than 
quantitative. Under non-steady state conditions, (i.e. the presence of insulin, competing 
substrates or ischemia) there is a discordant affinity of hexokinase for glucose versus FDG, 
with a stronger preference for glucose (Doenst and Taegtmeyer, 1998; Hariharan et al., 
1995). Non-steady state conditions lead to a change in the lumped constant (LC), which is, 
in fact, not a constant but rather a conversion factor used to convert the rates of tracer 
uptake to the rates of tracee uptake. However, the LC can be predicted using a time-activity 
curve generated from the measured rates of [2-3H]glucose and FDG glucose uptake under 
the same conditions (Bøtker et al., 1999).  
The steady-state glucose infusion rate was significantly increased in the sunitinib 
group (Figure 4.2.2B). Once steady-state conditions are reached, the rate of glucose 
infusion is equal to the rate of glucose disposal and the rate of peripheral glucose uptake 
can be approximated. The glucose disposal rate was significantly increased in the sunitinib 
group (Figure 4.2.2C) and [U-14C]-2DG uptake revealed a fivefold and sevenfold increase in 
the heart and skeletal muscle, respectively (Figure 4.2.2D).  
 
  
 Figure 4.2.1. 
Figure 4.2.1. Sunitinib increases systemic insulin sensitivity.
glucose levels. (B) Non-fasted serum insulin. 
course of treatment. (D) Insulin tolerance test. 
**P < 0.01.  
 
 (A) Non
(C) Average caloric intake per day over the 
(E) Oral glucose tolerance test. *P < 0.05 and
 
99 
 
-fasted serum 
 
 Figure 4.2.2. 
Figure 4.2.2. Hyperinsulinemic euglycemic clamp procedure in mice treated with 
sunitinib. (A) Summary of the clamp procedure. 
Glucose disposal rate calculated from the steady
deoxyglucose uptake in the heart and skeletal muscle. *P < 0.05, **P < 0.01 and ***P < 
0.001.  
 
(B) Steady-state glucose infusion rate. 
-state glucose disposal rate. 
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 A hallmark of the fetal heart is the reliance on glucose metabolism as the primary 
source of energy provision. The greater efficiency of glucose oxidation permits the fetal 
heart to adapt to its low oxygen environment and demand for growth. With exposure to the 
oxygen-rich post-natal environment and the rapid depletion of endogenous substrate stores, 
the heart rapidly switches to fatty acid oxidation. However, a salient feature of the failing 
heart is metabolic remodeling from predominant fatty acid oxidation to carbohydrate 
metabolism.  
Transcript analysis by qPCR revealed a significant upregulation of glycolytic genes, 
specifically pointing to the redirection of glucose towards lactate production (Figure 4.2.3A). 
This corresponded to reduced enzyme activity of pyruvate kinase (Figure 4.2.3B) and 
increased lactate dehydrogenase activity (Figure 4.2.3C). Hallmarks of the fetal gene 
program, which include a switch in the contractile protein isoforms from myosin heavy chain 
α (MHCα) to MHCβ and increased expression of atrial naturetic factor (ANF), c-myc and c-
fos (Rajabi et al., 2007), were increased in the sunitinib-treated hearts (Figure 4.2.3D). 
Thus, sunitinib treatment leads to upregulation of the fetal gene program in the heart. 
Upregulation of the fetal gene program and increased glycolysis are intimately linked with 
cardiac hypertrophy. Correspondingly, I observed an increase in cardiomyocyte cross-
sectional area in sunitinib-treated mice (Figure 4.2.3E). Interestingly, I did not observe an 
increase in the heart weight to body weight ratio, which suggests that cardiac hypertrophy 
and apoptosis occurs side-by-side and may be a unique feature of sunitinib cardiotoxicity 
(Figure 4.2.3F).  
4.2.3. Glucose is redirected into secondary pathways of metabolism. 
 Glycogen occupies about 2% of the cell volume in the adult cardiomyocyte, however 
comprises nearly a third of the cell volume in the fetal heart (Rajabi et al., 2007).  
 Figure 4.2.3. 
Figure 4.2.3. Sunitinib treatment increase
analysis by qPCR of key glycolytic genes. 
Lactate dehydrogenase enzyme activity. 
fetal gene program (E) Hemotoxylin and Eosin (H&
treated with sunitinib or vehicle. Cardiomyocyte cross
right. (F) Ratio of heart weight to body weight. *P < 0.05.
s glycolysis in the heart. 
(B) Enzyme activity of pyruvate kinase. 
(D) qPCR analysis demonstrating activation of the 
E) staining of cross sections from mice 
-sectional area is quantified to the 
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Correspondingly, I observed significant glycogen accumulation in sunitinib treated hearts 
(Figure 4.2.4A). This was suggestive of an overflow of glucose into secondary pathways of 
glucose metabolism. Accordingly, I observed a significant increase in O-Linked β-N-
acetylglucosamine (O-GlcNAc) modification of cardiac proteins (Figure 4.2.4B). O-GlcNAc 
is a product of the hexosamine biosynthetic pathway and results from conversion of glucose 
6-phosphate to fructose 6-phosphate, glucosamine-6-phosphate and ultimately to UDP-
GlcNAc (Ngoh et al., 2010; Watson et al., 2010). Similar to phosphorylation, it is rapidly 
cycled on and off proteins via the action of O-GlcNAc transferase and O-GlcNAcase. 
Sunitinib-induced cardiotoxicity is a unique model of cardiac dysfunction and it is unclear 
what the role of O-GlcNAcylation is in the sunitinib-treated heart.  
It is of note that in the hearts from sunitinib-treated animals, the levels of glucose-6-
phosphate are significantly decreased (Figure 4.2.4C). I have verified these measurements 
by repeated assays. The results suggest that G6P is metabolized by at least three different 
pathways: glycolysis, glycogen synthesis and the hexosamine biosynthetic pathway. Future 
work may determine the flux rates through the individual pathways. 
4.2.4. Sunitinib treatment leads to induction of PKM2. 
Increased glycolysis, slowed pyruvate kinase activity and redirection of glucose into 
secondary pathways of metabolism were reminiscent of the Warburg Effect in cancer. Since 
its first description by Otto Warburg, reviewed by (Warburg, 1956), the Warburg Effect has 
evolved to describe the upregulation of glycolysis by cancer cells and the redirection of 
glucose-derived carbons into biosynthetic pathways (Vander Heiden et al., 2009). One of 
the drivers of the Warburg Effect in cancer is the induction of the fetal, M2 isoform of 
pyruvate kinase (PKM2). Because I had observed activation of the fetal gene program in the 
sunitinib  
 Figure 4.2.4. 
Figure 4.2.4. Glucose is redirected into secondary pathways of glucose metabolism
(A) Cardiac glycogen content as assessed by Periodic Acid
right by tissue extraction and enzyme
demonstrating increased O
phosphate levels. *P < 0.05 and ***P < 0.001.
 
-Schiff staining and quantified to 
-coupled spectroscopy.  (B)
-GlcNAcylation of cardiac proteins. (C) Cardiac glucose 6
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treated heart, I asked whether PKM2 induction also occurs with sunitinib treatment. 
Digestion of the PKM cDNA product with the restriction enzyme Pst1 (Figure 4.2.5A) 
revealed a significant increase in the percentage of PKM2 in the heart (Figure 4.2.5B). This 
was confirmed by both western blot (Figure 4.2.5C) and qPCR (Figure 4.2.5D). Thus, in 
hearts from sunitinib treated mice, PKM2 is upregulated like in cancer cells.  
 
4.2.5. Sunitinib treatment leads to activation of Hif1α and c-myc.  
Under normoxic conditions, the master hypoxia response factor, hypoxia inducible 
factor 1α (Hif1α) is hydroxylated by a family of prolyl-hydroxylases and subsequently 
targeted for ubiquitin-mediated proteasomal degradation by the von Hippel–Lindau protein 
(VHL). When the oxygen level in the cell falls, Hif1α  translocates into the nucleus where it 
heterodimerizes with Hif1β and activates a host of genes, including PKM2. Hydroxylated 
PKM2, in turn, upregulates Hif1α expression in a positive feed-forward loop.  
Sunitinib treatment resulted in increased Hif1α protein expression in the nuclear 
fraction of hearts from mice treated with sunitinib (Figure 4.2.6A) as well as an upregulation 
of Hif1α transcript levels (Figure 4.2.6B) and transcript levels of Hif1α-induced genes 
(Figure 4.2.6C). This suggests that activation of Hif1α may be an important contributor to 
the induction of PKM2 in the heart.  
Alternative splicing of the PKM gene is dependent on three heterogeneous nuclear 
ribonucleoprotein (hnRNP) proteins: polypyrimidine tract binding protein (PTB, also known 
as hnRNPI), hnRNPA1 and hnRNPA2. At high levels, these factors bind to the intronic 
sequence flanking exon 9 and inhibit the inclusion of exon 9 (PKM1) in the mRNA product 
(Luo and Semenza, 2012). Upregulation of these factors is promoted by the oncogenic 
transcription factor c-myc (David et al., 2010). In the heart, c-myc is induced by pressure  
 Figure 4.2.5. 
Figure 4.2.5. Sunitinib treatment results in 
kinase. (A) Diagram detailing the alternative splicing of the PKM gene and resulting cDNA 
products and restriction enzyme sites. 
resulting percentage of PKM2, quantified to the right. 
PKM1 mice treated with sunitinib (S) or vehicle (V). 
PKM2 transcript levels. *P < 0.05. 
 
induction of the M2 isoform of pyruvate 
(B) Pst1 digest of the PKM cDNA products and 
(C) Western blotting of PKM2 and 
(D) qPCR quantification of PKM1 and 
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 Figure 4.2.6. 
Figure 4.2.6. Sunitinib treatments results in the activation of Hif1
Western blotting for Hif1α in the
measurement of Hif1α and (C)
of c-myc protein expression in the nuclear fraction of cardiac tissue lysates. 
analysis of c-myc and (F) of key PKM2 splicing factors induced by c
α and c
 nuclear fraction of cardiac tissue lysates. (B)
 Hif1α-target genes expression in the heart. (D)
-myc. *P < 0.05.
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overload (Mulvagh et al., 1988). Additionally, coronary flow is a strong determinant of c-myc 
expression (Bauters et al., 1988). Nuclear c-myc protein (Figure 4.2.6D) and mRNA (Figure 
4.2.6E) expression levels were significantly increased in sunitinib-treated hearts. Transcript 
levels of PTB, hnRNPA1 and hnRNPA2 were similarly increased in sunitinib treated hearts 
(Figure 4.2.6F). These findings further support the critical role of PKM2 expression (and the 
Warburg Effect) in hearts from sunitinib treated animals.  
 
4.2.6. Hif1α activation results in PKM2 induction in the heart.  
 In order to determine directly whether hypoxia was sufficient to induce PKM2 
expression in the heart, mice were housed in an 8% oxygen environment for 24 hours. As a 
result, PKM2 expression was increased in the heart, but not in skeletal muscle (Figure 
4.2.7A). I next determined whether PKM2 induction could be induced in vitro. Not 
unexpectedly, the immortalized cardiac cell line H9C2 and neonatal rat ventricular myocytes 
(NRVMs) only express PKM2 whereas isolated adult mouse cardiomyocytes express 
primarily PKM1 (Figure 4.2.7B). Thus the isolated adult cardiomyocytes proved ideal to 
study the induction of PKM2 in the heart. Twenty-four hour exposure of isolated adult 
cardiomyocytes to 1% oxygen or to the pharmacological hypoxia mimetics, 
dimethyloxalylglycine (DMOG) and cobalt chloride, resulted in increased PKM2 expression 
compared to sunitinib treatment or untreated controls (Figure 4.2.7C). These results are 
important because they indicate that the pyruvate kinase isoform switch is mediated by 
oxygen deprivation and not as a direct effect of sunitinib. 
 
4.2.7. PKM2 is induced in the failing human heart.  
 Figure 4.2.7. 
Figure 4.2.7. Hif1α activation
expression in mice subjected to normoxia (21% oxygen) or 8% oxygen for 24 hours. 
Percent PKM2 expression in the H9C2 cell line, neonatal rat ventricular myocytes (N
or isolated adult cardiomyocytes. 
cardiomyocytes exposed to 1% oxygen or treated with the pharmacological mimetics 
dimethyloxalylglycine (DMOG) or cobalt chloride (CoCl
 results in PKM2 induction in the heart. (A)
(C) Percent PKM2 expression in isolated adult 
2) for 24 hours. * P < 0.05.
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 To determine the clinical relevance of my findings I evaluated PKM2 expression in 
heart muscle samples from non-failing and failing human hearts, the latter before and after 
mechanical unloading with a left-ventricular assist device (LVAD). Compared to non-failing 
hearts, PKM2 expression, assessed by qPCR, was significantly increased in the failing heart 
muscle samples (Figure 4.2.8A). This observation was confirmed by western blot (Figure 
4.2.8B). It appeared that the induction of PKM2 regressed with mechanical unloading. I 
therefore evaluated PKM2 expression in a total of 13 paired samples and found a significant 
decrease in PKM2 expression in the explant heart muscle samples (Figure 4.2.8C). Similar 
to the mouse samples, PKM2 induction was correlated with O-GlcNAcylation of proteins in 
the human hearts (Figure 4.2.8D). The results confirm the lab’s earlier observations that the 
failing human heart reverts to the fetal genotype (Razeghi et al., 2001). They also show, for 
the first time, a partial reversal with mechanical unloading.  
 
4.3 Discussion 
     It has long been assumed that PKM2 is an oncogene, specifically selected by the 
tumor to drive growth. Yet the question remains why there is selection for PKM2 rather than 
a silencing or mutation of PKM1. A recent report from the Vander Heiden lab demonstrated 
that—surprisingly—deletion of PKM2 results in more aggressive tumors (Israelsen et al., 
2013). It seems that selection for PKM2 permits metabolic flexibility, allowing for either 
pyruvate generation or a redirection of glucose-derived carbons into biosynthetic pathways 
for growth. In the postmitotic cardiomyocyte, the role of PKM2 induction in the failing heart 
may have a similar role.  
Glucose metabolism in the hemodynamically stressed heart is finely regulated and 
can be both adaptive and maladaptive. For instance, overexpression of the glucose  
 Figure 4.2.8. 
Figure 4.2.8. Induction of PKM2 in the failing human heart
expression in non-failing, or failing human hearts before and after LVAD implantation. 
Protein expression of PKM2 and PKM1 in heart muscle samples. 
expression in paired heart muscle samples from before and after LVAD impl
Quantification of O-GlcNAcylated proteins in non
muscle samples at the time of LVAD implant (I) and explant (E) by Western Blot. *P < 0.05 
and **P < 0.01.  
. (A) 
(C) 
-failing and paired failing human heart 
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transporter, GLUT1, prevents the development of heart failure in response to pressure 
overload stress as well as protects from ischemic injury in both young and aged mice (Liao 
et al., 2002; Luptak et al., 2007). Knockdown of acetyl-CoA carboxylase 2 (ACC2) enhances 
rates of fatty acid oxidation, prevents hypertrophy and preserves cardiac function (Essop et 
al., 2008; Kolwicz et al., 2012). Similarly, high fat feeding prevents hypertrophy-induced 
cardiac remodeling in rats (Okere et al., 2006). However in our lab’s experience, preventing 
substrate switching via activation of peroxisome proliferator-activated receptor alpha 
(PPARα) exacerbates dysfunction in rat hearts subjected to pressure overload stress 
(Young et al., 2001).  
The uncoupling of glycolysis from glucose oxidation may be where the process 
begins to unravel (Taegtmeyer, 2000). The lab has also demonstrated that myocardial 
glucose uptake in excess of the oxidative capacity of the heart leads to contractile 
dysfunction through the accumulation of glucose 6-phosphate, sustained activation of the 
mammalian target of rapamycin (mTOR) and endoplasmic reticulum stress (Sen et al., 
2013). 
A simple question is does induction of PKM2 allow the failing heart to respond to 
uncertain nutrient and oxygen availability or does PKM2 exacerbate pathological 
hypertrophy and adverse remodeling? I propose that PKM2 induction is part of the adaptive 
response in the stressed heart. Unlike PKM1, which exists as a near-constitutively active 
tetramer, PKM2 can exist as a dimer or tetramer and is uniquely subject to allosteric 
regulation and various post-translational modifications that determine its function as 
pyruvate kinase, protein kinase or transcription factor (Anastasiou et al., 2012; Wong et al., 
2013). Importantly, the ability of PKM2 to rapidly cycle between a tetramer and dimer could 
be especially advantageous to the failing heart.  In its tetramer form, PKM2 acts as a 
canonical pyruvate kinase, allowing pyruvate oxidation and ATP generation. The low 
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catalytic activity of the dimer form slows glycolysis and allows for the redirection of glucose-
derived carbons into biosynthetic pathways promoting cell proliferation, in the case of 
cancer, or, in the case of the heart, intracellular self-renewal and hypertrophy. It will be 
important to determine if, similar to the Warburg effect in cancer, glucose-derived carbons 
support cardiac hypertrophy.  
It has also been proposed that “cellular oncogenes drive the progression to heart 
failure” (Hoshijima and Chien, 2002). This is based on the observation that many of the 
pathways driving tumor growth also drive cardiomyocyte hypertrophy (Cheng and Force, 
2010; Mulvagh et al., 1988). Induction of PKM2 in the hypertrophying heart would fit with this 
reasoning. Included in this original hypothesis was activation of the fetal gene, c-myc. In 
cancer, c-myc drives the expression of three heterogeneous nuclear ribonucleoprotein 
(hnRNP) proteins-polypyrimidine tract binding protein (PTB, also known as hnRNPI), 
hnRNPA1 and hnRNPA2-that are essential for preferential splicing of PKM2 (David et al., 
2010). Because c-myc transcription was significantly induced in the sunitinib treated hearts 
(Figure 4.2.6), it is possible that c-myc might also be important for preferential PKM2 
splicing in the heart. Furthering this hypothesis, changes in hemodynamic load induces c-
myc in the remodeling heart (Depre et al., 1998). As PKM2 expression seems to correlate 
with hemodynamic load in the failing human heart (Figure 4.2.8), it seems likely that c-myc 
plays a role in promoting PKM2 induction, though the exact mechanism awaits elucidation.  
Hif1α and dysregulated c-myc have been shown to cooperatively promote transcription of 
key glycolytic genes in cancer (Wong et al., 2013). However, in the adult heart, Hif1α and c-
myc seem to play opposing roles. Whether these two factors cooperate in the failing heart, 
or whether this is an anomaly of the sunitinib-treated heart, remains to be determined. 
Vander Heiden and colleagues specifically deleted PKM2 in tumor cells by inserting 
flox sites flanking exon 10 of the PKM gene. Cre-induced recombination led to selective 
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expression of PKM1 and a nonfunctional, truncated version of the PKM gene, PKM-skip, 
which included neither exon 9 or 10. Interestingly, PKM2 is not required for tumor formation 
or progression. The obvious next experiment would be to delete PKM2 in the hearts of mice 
exposed to pressure-overload stress. This would determine whether PKM2 induction is 
adaptive or maladaptive feature of the stressed heart. 
The reciprocal experiment would be to force PKM2 expression in the adult heart, 
perhaps by using a conditional deletion of PKM1 in the adult heart. This would address the 
“chicken or the egg” scenario with PKM2 expression and enhanced glucose uptake. 
Christofk and colleagues have demonstrated that knockdown of PKM2 in cancer cell lines 
decreased the rate of glycolysis and that reintroduction of PKM2 but not PKM1 enhanced 
glycolysis and xenograft tumor formation (Christofk et al., 2008). PKM2 induction in the heart 
is likely part of a coordinated response to hypoxic or hemodynamic stress in the heart. 
Furthermore, PKM2 induction is probably not the cause of the glycolytic switch but rather an 
important mediator.  
PKM2 is subject to profound allosteric regulation and post-translational modifications 
that regulate its function as a pyruvate kinase, protein kinase or transcription factor. These 
nonmetabolic functions of PKM2 may be similarly important in the failing heart. For instance, 
oxidation of cysteine 358 decreases PKM2 activity, leading to a redirection of glucose into 
the pentose phosphate pathway and generation of reducing equivalents. Dimeric PKM2 can 
also translocate into the nucleus, for instance in response to EGFR stimulation, and 
transactivate transcription factors such as β-catenin or the stem cell factor Oct4 (Lee et al., 
2008; Yang et al., 2011). PKM2 can use the high energy bonds from PEP to phosphorylate 
and activate proteins such as Stat3 (Gao et al., 2012).  Stat3 is important for proper function 
of the electron transport chain (Wegrzyn et al., 2009), and  cardiomyocyte-specific knockout 
of Stat3 accelerates inflammation-induced cardiac fibrosis (Jacoby et al., 2003).  
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Several small molecule activators of PKM2 have been developed and have proven to 
suppress tumor growth (Anastasiou et al., 2012; Parnell et al., 2013). Similar to the 
endogenous activator of PKM2, fructose-1,6-bisphopsphate (FBP), these molecules, namely 
DASA-58 (N, N′-diarylsulfonamide, NCGC001859) and TEPP-46 (thieno-[3,2-b]pyrrole [3,2-
d]pyridazinone, NCGC00186528), stabilize the high-activity tetramer conformation of PKM2 
allowing for flow of glucose through to pyruvate (Wong et al., 2013). Phosphorylation of 
tyrosine 105 by fibroblast growth factor receptor 1 (FGFR1) leads to FBP dissociation and 
destabilization of the tetramer formation. Importantly, small molecule activators of PKM2 that 
bind to this same FBP binding pocket are resistant to this phosphorylation (Wong et al., 
2013). More recently small molecule activators of PKM2 have been developed which bind to 
a distinct site from FBP and appear to be more effective (Anastasiou et al., 2012). The 
question remains whether stabilization of PKM2 tetramer formation would be advantageous 
to the failing heart by better matching glucose uptake and oxidation. Forced fatty acid 
oxidation (i.e. activation of PPARs with fenofibrate (Chicco et al., 2007) exacerbates 
dysfunction in the failing heart. It is unclear whether normalization of PKM2 function in the 
failing heart would be similarly detrimental. It is important to note that while these activators 
restore the pyruvate kinase activity of PKM2, the potentially advantageous nuclear signaling 
and protein kinase activities are lost. Thus these inhibitors may be a useful tool to delineate 
the two function of PKM2 in the heart.  
To my knowledge, this is the first evidence of PKM2 induction in any model of heart 
failure. The importance of secondary pathways of glucose metabolism in the heart is largely 
unrecognized beyond glycogen as an energetic store and redirection of glucose into the 
pentose phosphate pathways to maintain redox status in the failing heart (Doenst et al., 
2013). PKM2 induction may be just the tip of the Warburg Effect iceberg in the failing heart. 
  
 Figure 4.2.9. 
Figure 4.2.9. Summary. In the failing heart, activation of the hypoxia response factor HIf1
results in induction of the M2 isoform of pyruvate kinase. This leads to a redirection of 
glycose into secondary pathways of metabolism including lactate production, glycogen 
accumulation on O-GlcNAcylation of proteins. 
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Chapter 5           
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
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5.1 Summary of findings 
In my work, I explored mechanisms of cardiotoxicity due to the cancer 
chemotherapeutic agent, the receptor tyrosine kinase inhibitor sunitinib. My two major 
finding are that sunitinib denudes the coronary vasculature of an important constituent, its 
pericytes, and that sunitinib induces major metabolic changes in the heart which are 
consistent with metabolic and structural remodeling of the cardiomyocyte. I will now discuss 
the importance of my findings and how my findings may relate to each other.  
Coronary microvascular pericytes are a primary target of sunitinib-induced 
cardiotoxicity. Work in my previous lab demonstrated that inhibition of the essential 
prosurvival signal, PDGFRβ, leads to cell death and coronary microvascular dysfunction. As 
I will discuss in detail below, microvascular dysfunction is associated with myocardial 
hypoxia and with the induction of the fetal gene program. My further work focused on 
sunitinib-induced metabolic changes in the heart and resulted in the discovery of an 
additional member of the fetal gene program, the M2 isoform of pyruvate kinase (PKM2). 
Most importantly, PKM2 induction is a signature of not only sunitinib cardiotoxicity but is also 
a striking feature of the failing human heart. To my knowledge, this is the first evidence of 
PKM2 induction in any model of heart failure.  
This work began with the fact that cardiotoxicity due to cancer treatments is a major 
obstacle in effective cancer treatment. A patient may outlive his or her cancer only to 
succumb to heart failure in as little as five years (Go et al., 2013; Levy et al., 2002). The 
focus of my dissertation was therefore twofold: First, to elucidate the mechanism of sunitinib-
induced cardiotoxicity in order to develop a cardioprotective strategy in patients receiving 
sunitinib and, secondly, to use sunitinib-induced cardiotoxicity as a tool to identify novel 
pathways that contribute to the progression of heart failure. I have demonstrated success in 
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both areas. Thalidomide, or perhaps one of its derivatives, may prove to be a viable 
treatment for patients at high risk of developing cardiac dysfunction while receiving sunitinib. 
Possible mechanisms for this protective effect are discussed in Chapter 3. Additionally, 
PKM2 may represent a novel metabolic target for the treatment of heart failure, although it 
remains to be determined whether the upregulation of PKM2 is adaptive or maladaptive to 
cardiac stress (discussed in Chapter 4). 
The data presented here reveal two important things. First, microvascular pericytes 
are essential to maintain cardiac function in response to stress. This adds to a growing body 
of evidence suggesting that the coronary vasculature is more dynamic than previously 
recognized, reviewed by (Feigl, 1983) and (Gould et al., 2013). Secondly, PKM2 may be an 
important mediator of cardiac energy provision. However, the extent to which the Warburg 
Effect exists in the heart remains to be determined. The relevance of these two observations 
to non-chemotherapy related heart failure is still to be proven and beyond the scope of my 
thesis. Clearly, more work is necessary to elucidate the mechanisms driving these two 
observations. Particular areas of future work are discussed below. 
 
5.2 Does pericyte loss result in myocardial hypoxia? 
One of my most important observations was establishing the fact that sunitinib 
treatment alone does not induce PKM2 expression in isolated adult cardiomyocytes (Figure 
4.2.7). This suggests that PKM2 induction through Hif1α may be secondary to the depletion 
of pericytes. In support of this hypothesis, deletion of either PDGF-B or PDGFRβ results in 
pericyte loss and leads to impaired perfusion and tissue hypoxia in the developing mouse 
brain (Hellström et al., 2001). Pericyte loss also leads to tissue hypoxia in a model of 
ischemic retinopathy (Wilkinson-Berka et al., 2004) and hypoxia-associated epithelial-to-
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mesenchymal transition and increased metastasis was linked to pericyte loss in a mouse 
model of breast cancer (Cooke et al., 2012). Collectively, these studies demonstrate that 
pericyte loss can lead to tissue hypoxia, and my results now suggest the same may be true 
for the heart. 
To induce deletion of pericytes in the breast tumors, the group of Cook et al. 
employed an inventive strategy, which could be used to determine whether PKM2 induction 
is secondary to pericyte loss and hypoxia in the heart (Cooke et al., 2012). The NG2 and, 
separately, PDGFRβ promoter was used to drive expression of the viral thymidine kinase 
(TK) in pericytes. Subsequent treatment with the antiviral drug ganciclovir led to selective 
cell death in TK-expressing cells, due to the fact that viral TK converts the nontoxic 
ganciclovir into a toxic metabolite (Barese et al., 2012). This approach may be 
advantageous over traditional methods that induce pericyte cell death, such as deletion of 
PDGF-B or PDGFRβ because the TK-ganciclovir approach would avoid the use of a Cre 
recombinase, which can be cardiotoxic at high levels (Buerger et al., 2006).  
Thalidomide co-treatment may also be a useful tool to determine whether PKM2 
induction is secondary to pericyte loss. In the first part of my thesis, I demonstrated that 
thalidomide can restore pericyte coverage. Thus, if protection of microvascular pericytes 
with thalidomide is sufficient to prevent induction of PKM2, it may be concluded that pericyte 
loss leads to PKM2 induction. However, there are several issues with this approach, 
particularly the non-specific nature of both sunitinib and thalidomide. Therefore a genetic 
approach, such as the TK-ganciclovir approach described above, would yield a more 
definitive answer, and I did not pursue this line of research.  
In addition to the regulation of capillary diameter (discussed in chapter 3), the 
diffusion distance that oxygen much travel from its dissociation from hemoglobin, across the 
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endothelium and finally to the mitochondria is crucially important in determining oxygen 
levels within the cell. This is illustrated by the Krogh cylinder model, which relates the radius 
of a capillary to the radius of a theoretical cylinder of tissue to which it supplies oxygen 
(Figure 5.1) (Fishman, 1982). The ratio of the cross-sectional area of the capillary to the 
cross-sectional area of the cylinder is directly proportional to the decrease in oxygen 
pressure from the capillary to that point. For example in Figure 5.1, a cell 10 units away 
from a capillary that has a radius of 5 units results in a ratio of 1:4. Therefore, if the arterial 
pO2 is 80 mmHg, the pO2 at that cell would be 20 mmHg.  However if this distance is 
doubled, the pO2 at the level of the cell would only be 5 mmHg, which would be sufficient to 
induce Hif1α activation. 
 In my model of sunitinib-induced pericyte loss, this distance may increase due to 
interstitial edema resulting from increased vessel leakiness (Figure 3.2.6). Although it does 
not likely double, the extent of interstitial edema was not measured in my experiments. It is 
also important to stress that the pO2 within the capillary does not remain constant along the 
length of the capillary. As oxygen is extracted by the tissue the intracapillary pO2 declines. 
This, coupled to decreased oxygen gradients at more distal sites and turbulent flow, would 
suggest that there are areas within the sunitinib treated heart where the pO2 falls to critically 
low levels.  
The existence of hypoxia in vivo is prohibitively difficult to prove. Precise 
measurement of cellular PO2 with an oxygen electrode is the definitive method to establish 
the presence of hypoxia (Krogh, 1919a, b). However, this is not always technically possible. 
Hypoxyprobe (pimonidazole HCl) is a commercially available tracer that can be used to label 
hypoxic areas in vivo (Hypoxyprobe, NPI Inc., Burlington, MA). Pimonidazole is stabilized 
under hypoxic conditions and binds to peptide thiols such as glutathione (Hodgkiss, 1998).  
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Figure 5.1 
 
 
Figure 5.1. The Krogh cylinder model of an oxygen pressure field. The pO2 at a given 
distance (R) from the capillary is directly proportional to the ratio of the capillary cross-
sectional area to the cross-sectional area of the theoretical cylinder to which it supplies 
oxygen.  For instance, at a point that is 10 units from a capillary that has a radius of 5 units 
results in a ratio of 1 to 4. Thus, if the capillary has a pO2 of 80mmHg, the pO2 at that point 
would be 20mmHg. Source: B. J. McGuire , T. W. Secomb. (1985) A theoretical model for 
oxygen transport in skeletal muscle under conditions of high oxygen demand. J Appl. 
Physiol. Reused with permission from the journal.  
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Fixed tissue sections or tissue lysates can then be probed with an antibody directed against 
pimonidazole. My attempt to use this probe in my sunitinib-treated mice resulted in false- 
positive staining in my control mice, perhaps due to incomplete washout of the probe before 
sacrifice. I therefore decided to abandon this approach.  
Another approach could be to use positron emission tomography (PET) imaging with 
18F-fluoromisonidazole (Rasey et al., 1996). Similar to pimonidazole, fluoromisonidazole is 
stabilized under hypoxic conditions and has been used to image hypoxic regions in both 
human and mouse tumors (Bentzen et al., 2002; Rajendran et al., 2004). Use of this probe 
in sunitinib treated mice or in conjunction with a model of pericyte loss, such as the TK-
ganciclovir approach suggested above, would help establish whether pericyte loss results in 
myocardial hypoxia.  
Still, it is entirely possible that sunitinib treatment leads to Hif1α stabilization 
irrespective of a change in cellular PO2. Sustained mTOR activation through loss of TSC2 
has been shown to stabilize Hif1α and induce PKM2 expression in mouse kidney tumors 
(Sun et al., 2011). Similarly, preliminary evidence from my lab indicates that conditional 
deletion of tuberous sclerosis 2 (TSC2), and therefore activation of mTOR, in the adult heart 
leads to PKM2 induction (Davogustto, unpublished observations). Additionally, oleanolic 
acid has been shown to repress PKM2 expression in isolated cancer cell lines (Liu et al., 
2014).  In addition to inducing pressure overload stress (discussed in Chapter 4), it will be 
interesting to determine whether other mechanisms, such as mTOR activation or metabolic 
stress, can induce PKM2 in the heart.  
 
5.3 Sunitinib as an insulin sensitizing agent. 
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The induction of PKM2 is not likely the cause of enhanced systemic insulin sensitivity 
during sunitinib treatment. As discussed in the previous chapter, it has been proposed that 
sunitinib decreases blood glucose levels though preservation of pancreatic beta cells 
(Hagerkvist et al., 2008; Han et al., 2009; Louvet et al., 2008). However, sunitinib also 
reduces blood glucose levels in both non-diabetic mice and in humans (Billemont et al., 
2008; Breccia et al., 2005; Breccia et al., 2004; Louvet et al., 2008; Mokhtari and Welsh, 
2010; Templeton et al., 2008; Tsapas et al., 2008; Veneri et al., 2005). Therefore, it seems 
likely that sunitinib increases peripheral insulin sensitivity. In normal insulin responsive cells, 
such as cardiomyocytes, activation of the PI3K-Akt signaling cascade by the binding of 
insulin to the insulin receptor leads to increased glucose uptake though trafficking of glucose 
transporters (primarily GLUT4) to the cell surface (James et al., 1989). However, similar to 
the VEGFRs and PDGFRs, the insulin receptor is a receptor tyrosine kinase, making it 
unlikely that sunitinib would increase insulin sensitivity through activation of the insulin 
receptor. However sunitinib may alter increase GLUT4 translocation or inhibit its endocytosis 
from the plasma membrane (Martin et al., 1999).  
In the treatment of diabetes, enhanced insulin sensitivity is achieved through 
pharmacological modulation of several pathways. The group of insulin-sensitizing agents 
known as thiazolidinediones (TZDs), improve insulin sensitivity by lowering plasma free fatty 
acids and activating peroxisome proliferator-activated receptor gamma (PPARγ). PPARγ 
regulates the expression of multiple metabolic enzymes (Spiegelman, 1998).  In rats, the 
TZD rosiglitazone increases GLUT4 expression (Oakes et al., 1994). Therefore, modulation 
of PPARγ could be a mechanism by which sunitinib increases insulin sensitivity. 
Metformin also increases insulin sensitivity in the peripheral tissues. This is achieved 
primarily though decreasing hepatic gluconeogenesis (Stumvoll et al., 1995). However, 
metformin also activates AMP-activated protein kinase (AMPK) (Zhou et al., 2001a) and has 
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been shown to increase glucose uptake in vitro (Bertrand et al., 2006). Conversely, sunitinib 
may directly inhibit AMPK (Kerkela et al., 2009; Laderoute et al., 2010). Sunitinib treatment 
is also associated with increased hepatic glucose production, as measured during the 
hyperinsulinemic euglycemic clamp procedure (Figure 4.2.2). Therefore, it is not likely that 
sunitinib enhances insulin sensitivity in a manner similar to metformin. 
It is, however, possible that sunitinib-induced pericyte loss directly enhances insulin 
sensitivity. The laboratory of Alan Attie at The University of Wisconsin-Madison has 
suggested that pericyte loss leads to increased transendothelial transport of insulin, allowing 
enhanced delivery of insulin to the muscle cell (Raines et al., 2011; Richards et al., 2010). In 
support of this hypothesis, pericyte loss in a rat model of diabetic retinopathy is associated 
with increased expression of genes involved in vesicular transport such as caveolin-1 and 
plasmalemmal vesicle associated protein-1 (PV-1) (Klaassen et al., 2009).  
Alternatively, because sunitinib is a highly promiscuous kinase inhibitor, it’s entirely 
possible that a unique combination of kinase inhibition leads to enhanced insulin sensitivity 
and glucose uptake in the sunitinib-treated animal. For this reason, I suspect that a 
proteomic approach would be useful to elucidate the mechanism of enhanced insulin 
sensitivity associated with sunitinib treatment. This is, however, beyond the scope of my 
thesis.  
 
5.4. Why do only a fraction of sunitinib-treated patients develop cardiac dysfunction? 
A vexing question is why only approximately 20% of patients develop cardiac 
dysfunction while on sunitinib. Assuming sunitinib also induces pericyte loss in humans, 
what is unique about the vasculature of these patients that makes them sensitive to 
sunitinib? Interestingly, patients who develop hypertension while receiving sunitinib have 
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significantly better responses to treatment and longer progression-free survival, suggesting 
that there is something different about the vasculature of these patients (Bono et al., 2011; 
Rini et al., 2011)). Yet the question remains, how do we determine what that difference is, 
and how can it be used to better inform treatment strategies? 
This question is of course not limited to sunitinib cardiotoxicity. Predicting whether a 
patient will respond to a given treatment spans all avenues of human disease and is the 
foundation of personalized medicine. My previous lab attempted to answer a similar 
question: what determines the time of transplant-free survival in a patient with new onset 
non-ischemic cardiomyopathy. That is, what determines whether a patient will remain stable 
for some time or will rapidly decompensate, in need of mechanical assist and/or need 
cardiac transplantation. By performing microRNA profiling on endomyocardial biopsies 
obtained from a small number of patients (10), my previous lab found that differential 
regulation of three microRNAs was predictive of outcome (unpublished data). Similarly, my 
current lab found that lower expression of two microRNAs, miRs 23a and 195, was 
associated with functional recovery in patients placed on a LVAD compared to patients who 
remained LVAD-dependent (Ramani et al., 2011). However, other tools may be more 
predictive of the development of cardiac dysfunction with sunitinib such as proteomics or 
epigenetic analysis. None of this has been attempted as yet. 
5.5. Future Directions 
My dissertation work revealed two important new findings: the necessity of 
microvascular pericyte coverage in preserving cardiac function and the induction of PKM2 in 
the failing heart. Sunitinib cardiotoxicity is, admittedly, not a robust model of heart failure 
because, due to the nonspecific nature of the drug, the mechanisms driving certain 
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observations are difficult to discern. Furthermore, it is unclear whether inhibition of these 
pathways is relevant to other models of heart failure.  
Irrespective of any mechanisms, my findings indicate extensive remodeling of the 
heart, akin to the remodeling observed in cancer cells. In cancer cells, glucose metabolism 
is redirection from oxidation, and to some extent also from glycolysis, to a host of 
biosynthetic pathways including the pentose phosphate pathway (Figure 5.2) and reviewed 
by (Vander Heiden et al., 2009). Increased flux through the pentose phosphate provides 
reducing equivalents (NADPH) and precursors for nucleotide synthesis (ribose) and 
nonessential amino acids, both of which are necessary for cell growth and division. 
Furthermore, the increased reliance on glutamine by cancer cells leads to production of 
acetyl-CoA for lipid biosynthesis via cycling through citrate. Mutations in key regulators of 
these pathways, such as in LKB1, p53 and c-myc, enable cancer cells to redirect glucose 
and glutamine into these biosynthetic pathways and proliferate uncontrollably. 
The main difference between the Warburg Effect in cancer and in the heart is that 
cancer cells hypertrophy and proliferate (Vander Heiden et al., 2009) while heart muscle 
cells hypertrophy and fail (Sen et al., 2013). However the pathways driving cellular 
hypertrophy in both cases may be very much the same. In addition to providing a more 
efficient fuel source, the switch to predominant glucose metabolism in the stressed heart 
may also support hypertrophy. The Warburg Effect may not be entirely applicable to the 
hypoxic heart, such as in the case of sunitinib cardiotoxicity, because it seems unlikely that 
the heart would synthesize new proteins under conditions of limited oxygen availability. 
However, increased O-GlcNAcylation of proteins may be part of the hypoxic response. 
Increased hexosamine and protein O-GlcNAcylation is protective in the setting of ischemia-
reperfusion (Jensen et al., 2012). Nonetheless, in response to other stresses such as 
pressure overload or even exercise, the Warburg Effect may be a previously unrecognized  
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Figure 5.2 
 
Figure 5.2. The Warburg Effect in cancer cells. The Warburg Effect is controlled by 
pathways involving known oncogenes and tumor suppressors. [Source: Vander Heiden, 
M.G., Cantley, L.C., and Thompson, C.B. (2009). Understanding the Warburg Effect: The 
Metabolic Requirements of Cell Proliferation. Science 324, 1029-1033. (Vander Heiden et 
al., 2009), reprinted with permission from the AAAS].
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mechanism through which the heart obtains carbons and reducing equivalents for cardiac 
hypertrophy.  
An important future experiment would be to trace glucose-derived carbons during 
pressure overload induced hypertrophy. The specifics of this experiment would be difficult to 
perform in vivo because cardiac hypertrophy requires at least a couple of weeks. It might be 
possible to introduce [U-13C]glucose into the chow of mice that have undergone transverse 
aortic banding. However, analysis of these findings may be confounded by the dynamic 
nature of protein turnover in the heart (Razeghi et al., 2003). Examination of the Warburg 
Effect in cancer does not have this problem because cancer cells rapidly proliferate in 
culture. As little as 6 hours of incubation with [U-13C]glucose or [U-13C]glutamine was 
sufficient to trace the incorporation of these carbons into biosynthetic pathways via gas 
chromatography-mass spectrometry (Mullen et al., 2012). A similar experiment could be 
performed in cultured cardiomyocytes. Cultured neonatal rat cardiomyocytes hypertrophy in 
response to norepinephrine (Simpson, 1983; Simpson, 1985). However as my work has 
demonstrated, neonatal rat cardiomyocytes already express PKM2, a hallmark of the 
Warburg Effect (Figure 4.2.7). Therefore, this experiment would need to be performed in 
isolated adult cardiomyocytes. Stimulation of isolated adult feline cardiomyocytes with TNF-
α is sufficient to induce hypertrophy (Yokoyama et al., 1997) and therefore these 
experiments are feasible. Additionally, the Warburg Effect is highly reliant on glutamine for 
citrate and acetyl-CoA for the synthesis of fatty acids (Mullen et al., 2012). Future 
experiments evaluating the Warburg Effect in the hypertrophying heart may also focus on 
glutamine metabolism.   
Assuming that glucose- or glutamine-derived carbons support cardiac hypertrophy, 
the next step would be to determine the mechanisms driving this effect. For instance, our lab 
has demonstrated that sustained activation of mTOR leads to uncontrolled protein synthesis 
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and endoplasmic reticulum stress in the heart (Sen et al., 2013). Based on these findings, 
we developed mice in which the negative regulator of mTOR, TSC2, can be conditionally 
deleted. Preliminary evidence suggests that this leads to an induction of PKM2 in the heart. 
AMPK may also mediate the Warburg Effect. As my lab has shown, AMPK regulated protein 
turnover through the E3 ligases Atrogin-1 and MuRF1 (Baskin and Taegtmeyer, 2011). 
Finally, as discussed in Chapter 4, I also predict that c-myc plays an important role in 
mediating the Warburg Effect in the heart. It will be interesting to determine if driving c-myc 
expression in the heart is sufficient to induce the Warburg Effect in the heart.  
Further work will determine how these findings will be leveraged for the development 
of novel treatments for human heart failure. At this point, there are certainly more questions 
than answers. Yet, in the words of Albert Einstein, “scientific endeavor is a natural whole the 
parts of which mutually support one another in a way which, to be sure, no one can 
anticipate” (Einstein, 2011). 
  
 Figure 5.3 
Figure 5.3 Summary of findings.
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